Search for a doctor

Gregory J. Gores, M.D.

  1. Gastroenterologist
  2. Internist
  3. Transplant Hepatologist
Request an Appointment

Publications

  1. Tomlinson JL, Li B, Yang J, Loeuillard E, Stumpf HE, Kuipers H, Watkins R, Carlson DM, Willhite J, O'Brien DR, Graham RP, Chen X, Smoot RL, Dong H, Gores GJ, Ilyas SI. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma. J Hepatol. 2024 Jun; 80 (6):892-903 Epub 2024 Mar 07
    View PubMed
  2. Wong CC, Tapper EB, Malhi H, Gores GJ. Manuscript best practices: Takeaways from a community conversation. Hepatology 2024 Jun 1; 79 (6):1243-1245 Epub 2024 Mar 11
    View PubMed
  3. Garcia Moreno AS, Guicciardi ME, Wixom AQ, Jessen E, Yang J, Ilyas SI, Bianchi JK, Pinto E Vairo F, Lazaridis KN, Gores GJ. IL-17 signaling in primary sclerosing cholangitis patient-derived organoids. Hepatol Commun. 2024 Jun 1; 8 (6) Epub 2024 June 03
    View PubMed
  4. Watkins R, Gamo A, Choi SH, Kumar M, Buckarma E, McCabe C, Tomlinson J, Pereya D, Lupse B, Geravandi S, Werneburg NW, Wang C, Starlinger P, Zhu S, Li S, Yu S, Surakattula M, Baguley T, Ardestani A, Maedler K, Roland J, Nguyen-Tran V, Joseph S, Petrassi M, Rogers N, Gores G, Chatterjee A, Tremblay M, Shen W, Smoot R. A small molecule MST1/2 inhibitor accelerates murine liver regeneration with improved survival in models of steatohepatitis. PNAS Nexus. 2024 Mar; 3 (3):pgae096 Epub 2024 Mar 01
    View PubMed
  5. Yang Y, Wang J, Wan J, Cheng Q, Cheng Z, Zhou X, Wang O, Shi K, Wang L, Wang B, Zhu X, Chen J, Feng D, Liu Y, Jahan-Mihan Y, Haddock AN, Edenfield BH, Peng G, Hohenstein JD, McCabe CE, O'Brien DR, Wang C, Ilyas SI, Jiang L, Torbenson MS, Wang H, Nakhleh RE, Shi X, Wang Y, Bi Y, Gores GJ, Patel T, Ji B. PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice. J Hepatol. 2024 Feb 28 [Epub ahead of print]
    View PubMed
  6. Emiloju OE, Yin J, Koubek E, Reid JM, Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA, Davis SL, Gores GJ, Roberts LR, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. Invest New Drugs. 2024 Feb; 42 (1):127-135 Epub 2024 Jan 25
    View PubMed
  7. Krishnan A, Ozturk NB, Cutshaw KA, Guicciardi ME, Kitagataya T, Olson KE, Pavelko KD, Sherman W, Wixom AQ, Jalan-Sakrikar N, Baez-Faria M, Gutierrez F, Gores GJ. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) deletion in myeloid cells augments cholestatic liver injury. Sci Rep. 2024 Jan 25; 14 (1):2145
    View PubMed
  8. Shah A, Jones MP, Callaghan G, Fairlie T, Ma X, Culver EL, Stuart K, De Cruz P, O'Beirne J, Tabibian JH, Dignass A, Canbay A, Gores GJ, Holtmann GJ. Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis. Hepatol Commun. 2024 Jan 1; 8 (1) Epub 2024 Jan 11
    View PubMed
  9. Marya NB, Hartley C, Powers PD, Bois MC, Kerr SE, Graham RP, Levy MJ, UMass-Mayo Clinic AI Cytopathology Consortium, Gleeson F, Abu Dayyeh BK, Bofill-Garcia A, Chandrasekhara V, Gores G, Kipp B, Law RJ, Petersen B, Roberts LR, Storm AC, Vargas Valls EJ. Development of a Computer-aided Prediction Tool for Evaluating Brushing Samples of Biliary Strictures. Clin Gastroenterol Hepatol. 2024 Jan; 22 (1):185-187.e3 Epub 2023 Mar 24
    View PubMed
  10. Lozada ME, Zhang N, Jin W, Wongjarupong N, Yang JD, Voss MM, Prasai K, Amakye DO, Harmsen WS, Chaudhary S, Bathe OF, Borad MJ, Patel TC, Gores GJ, Therneau TM, Roberts LR. CS-iCCA, A New Clinically Based Staging System for Intrahepatic Cholangiocarcinoma: Establishment and External Validation. Am J Gastroenterol. 2023 Dec 1; 118 (12):2173-2183 Epub 2023 Mar 20
    View PubMed
  11. Malhi H, Brown RS Jr, Lim JK, Reau N, Tapper EB, Wong CC, Gores GJ. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatology. 2023 Dec 1; 78 (6):1680-1681 Epub 2023 Nov 09
    View PubMed
  12. Malhi H, Brown RS Jr, Lim JK, Reau N, Tapper EB, Wong CC, Gores GJ. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Liver Transpl. 2023 Dec 1; 29 (12):1262-1263 Epub 2023 Nov 09
    View PubMed
  13. Malhi H, Gores GJ. Introducing the Editorial Fellow and the Fellows' Corner. Hepatology. 2023 Dec 1; 78 (6):1677 Epub 2023 Nov 16
    View PubMed
  14. Malhi H, Brown RS Jr, Lim JK, Reau N, Tapper EB, Wong CC, Gores GJ. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Clin Liver Dis (Hoboken). 2023 Dec; 22 (6):193-194 Epub 2023 Nov 09
    View PubMed
  15. Malhi H, Brown RS Jr, Lim JK, Reau N, Tapper EB, Wong CC, Gores GJ. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatol Commun. 2023 Nov 1; 7 (11) Epub 2023 Nov 09
    View PubMed
  16. Affo S, Filliol A, Gores GJ, Schwabe RF. Fibroblasts in liver cancer: functions and therapeutic translation. Lancet Gastroenterol Hepatol. 2023 Aug; 8 (8):748-759 Epub 2023 June 26
    View PubMed
  17. Malhi H, Shah V, Gores GJ. Thematic reviews: The future of hepatology. Hepatology 2023 Aug 1; 78 (2):388 Epub 2023 Apr 19
    View PubMed
  18. Engel BJ, Paolillo V, Uddin MN, Gonzales KA, McGinnis KM, Sutton MN, Patnana M, Grindel BJ, Gores GJ, Piwnica-Worms D, Beretta L, Pisaneschi F, Gammon ST, Millward SW. Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging. Cancers (Basel). 2023 Jul 26; 15 (15) Epub 2023 July 26
    View PubMed
  19. Calvisi DF, Boulter L, Vaquero J, Saborowski A, Fabris L, Rodrigues PM, Coulouarn C, Castro RE, Segatto O, Raggi C, van der Laan LJW, Carpino G, Goeppert B, Roessler S, Kendall TJ, Evert M, Gonzalez-Sanchez E, Valle JW, Vogel A, Bridgewater J, Borad MJ, Gores GJ, Roberts LR, Marin JJG, Andersen JB, Alvaro D, Forner A, Banales JM, Cardinale V, Macias RIR, Vicent S, Chen X, Braconi C, Verstegen MMA, Fouassier L, CCA Model Consortium. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. Nat Rev Gastroenterol Hepatol. 2023 Jul; 20 (7):462-480 Epub 2023 Feb 08
    View PubMed
  20. Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, Gores GJ. Cholangiocarcinoma - novel biological insights and therapeutic strategies. Nat Rev Clin Oncol. 2023 Jul; 20 (7):470-486 Epub 2023 May 15
    View PubMed
  21. Kang JH, Splinter PL, Trussoni CE, Pirius NE, Gores GJ, LaRusso NF, O'Hara SP. The Epigenetic Reader, Bromodomain Containing 2, Mediates Cholangiocyte Senescence via Interaction With ETS Proto-Oncogene 1. Gastroenterology. 2023 Jul; 165 (1):228-243.e2 Epub 2023 Apr 12
    View PubMed
  22. Kang JH, Splinter PL, Trussoni CE, Pirius NE, Gores GJ, LaRusso NF, O'Hara SP. The epigenetic reader, bromodomain containing 2, mediates cholangiocyte senescence via interaction with ets proto-oncogene 1. Gastroenterology. 2023 Jul; 165 (1):228-43.e2
  23. Dohnalkova E, Bayer RL, Guo Q, Bamidele AO, Kim Lee HS, Valenzuela-Pérez L, Krishnan A, Pavelko KD, Guisot NES, Bunyard P, Kim YB, Ibrahim SH, Gores GJ, Hirsova P. Rho-associated protein kinase 1 inhibition in hepatocytes attenuates nonalcoholic steatohepatitis. Hepatol Commun. 2023 Jun 01; 7(6). Epub 2023 Jun 02.
    View PubMed
  24. Eshmuminov D, Studer DJ, Lopez Lopez V, Schneider MA, Lerut J, Lo M, Sher L, Musholt TJ, Lozan O, Bouzakri N, Sposito C, Miceli R, Barat S, Morris D, Oehler H, Schreckenbach T, Husen P, Rosen CB, Gores GJ, Masui T, Cheung TT, Kim-Fuchs C, Perren A, Dutkowski P, Petrowsky H, Thiis-Evensen E, Line PD, Grat M, Partelli S, Falconi M, Tanno L, Robles-Campos R, Mazzaferro V, Clavien PA, Lehmann K. Controversy Over Liver Transplantation or Resection for Neuroendocrine Liver Metastasis: Tumor Biology Cuts the Deal. Ann Surg. 2023 May 1; 277 (5):e1063-e1071 Epub 2022 Aug 17
    View PubMed
  25. Malhi H, Gores GJ. Letters to the Editor: defining utility and pertinence. Hepatology. 2023 Apr 1; 77 (4):1069-1070 Epub 2023 Feb 03
    View PubMed
  26. Starlinger P, Brunnthaler L, McCabe C, Pereyra D, Santol J, Steadman J, Hackl M, Skalicky S, Hackl H, Gronauer R, O'Brien D, Kain R, Hirsova P, Gores GJ, Wang C, Gruenberger T, Smoot RL, Assinger A. Transcriptomic landscapes of effective and failed liver regeneration in humans. JHEP Rep. 2023 Apr; 5 (4):100683 Epub 2023 Feb 02
    View PubMed
  27. Abdelrahman AM, Yin J, Alva-Ruiz R, Yonkus JA, Leiting JL, Lynch IT, Fogliati A, Campbell NA, Carlson DM, Roberts LR, Gores GJ, Smoot RL, Graham RP, Halfdanarson TR, Truty MJ. Mixed Acinar Neuroendocrine Carcinoma of the Pancreas: Comparative Population-Based Epidemiology of a Rare and Fatal Malignancy in The United States. Cancers (Basel). 2023 Jan 30; 15 (3)
    View PubMed
  28. Conboy CB, Yonkus JA, Buckarma EH, Mun DG, Werneburg NW, Watkins RD, Alva-Ruiz R, Tomlinson JL, Guo Y, Wang J, O'Brien D, McCabe CE, Jessen E, Graham RP, Buijsman RC, Vu D, de Man J, Ilyas SI, Truty MJ, Borad M, Pandey A, Gores GJ, Smoot RL. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma. J Hepatol. 2023 Jan; 78 (1):142-152 Epub 2022 Sept 24
    View PubMed
  29. Grant CW, Juran BD, Ali AH, Schlicht EM, Bianchi JK, Hu X, Liang Y, Jarrell Z, Liu KH, Go YM, Jones DP, Walker DI, Miller GW, Folseraas T, Karlsen TH, LaRusso NF, Gores GJ, Athreya AP, Lazaridis KN. Environmental chemicals and endogenous metabolites in bile of USA and Norway patients with primary sclerosing cholangitis. Exposome. 2023; 3 (1):osac011 Epub 2023 Jan 05
    View PubMed
  30. Takaichi S, Mun DG, Yu M, Tomlinson JL, Abdelrahman AM, Carlson DM, Werneburg NW, Wu X, Pandey A, Gores GJ, Smoot RL. LCK and resistance to cytotoxic chemotherapy via activating an AXL-PEAK1 signaling axis in cholangiocarcinoma. JCO Global Oncology. 2023; 9:27
  31. Singh Y, Jons WA, Eaton JE, Vesterhus M, Karlsen T, Bjoerk I, Abildgaard A, Jorgensen KK, Folseraas T, Little D, Gulamhusein AF, Petrovic K, Negard A, Conte GM, Sobek JD, Jagtap J, Venkatesh SK, Gores GJ, LaRusso NF, Lazaridis KN, Erickson BJ. Algebraic topology-based machine learning using MRI predicts outcomes in primary sclerosing cholangitis. Eur Radiol Exp. 2022 Nov 18; 6(1):58.
    View PubMed
  32. Breuer E, Mueller M, Doyle MB, Yang L, Darwish Murad S, Anwar IJ, Merani S, Limkemann A, Jeddou H, Kim SC, Lopez-Lopez V, Nassar A, Hoogwater FJH, Vibert E, De Oliveira ML, Cherqui D, Porte RJ, Magliocca JF, Fischer L, Fondevila C, Zieniewicz K, Ramirez P, Foley DP, Boudjema K, Schenk AD, Langnas AN, Knechtle S, Polak WG, Taner CB, Chapman WC, Rosen CB, Gores GJ, Dutkowski P, Heimbach JK, Clavien PA. Liver Transplantation as a New Standard of Care in Patients With Perihilar Cholangiocarcinoma? Results From an International Benchmark Study. Ann Surg. 2022 Nov 1; 276 (5):846-853 Epub 2022 July 27
    View PubMed
  33. Pery R, Smoot RL, Thiels CA, Cleary SP, Vierkant RA, Ilyas SI, Gores GJ, Nagorney DM. Hepatobiliary and pancreatic resection for cholangiocarcinoma in patients with primary sclerosing cholangitis. Br J Surg. 2022 Oct 14; 109 (11):1032-1035
    View PubMed
  34. Ji H, Barr Fritcher EG, Yin J, Bainter TM, Zemla TJ, Gores GJ, Halling KC, Kipp BR, Roberts LR. Evaluating the Significance of Pancreatobiliary Fluorescence In Situ Hybridization Polysomy on Prognosis in De Novo Cholangiocarcinoma. Clin Transl Gastroenterol. 2022 Oct 1; 13 (10):e00523 Epub 2022 Oct 01
    View PubMed
  35. Buckarma E, De La Cruz G, Truty M, Nagorney D, Cleary S, Kendrick M, Borad M, Graham RP, Gores G, Smoot R. Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection. HPB (Oxford). 2022 Oct; 24 (10):1748-1756 Epub 2022 May 28
    View PubMed
  36. Lee YT, Singal AG, Lauzon M, Agopian VG, Luu M, Noureddin M, Todo T, Kim IK, Friedman ML, Kosari K, Nissen NN, Roberts LR, Heimbach JK, Gores GJ, Yang JD. Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States. Cancer. 2022 Oct; 128 (20):3610-3619 Epub 2022 Aug 23
    View PubMed
  37. Watkins RD, Buckarma EH, Tomlinson JL, McCabe CE, Yonkus JA, Werneburg NW, Bayer RL, Starlinger PP, Robertson KD, Wang C, Gores GJ, Smoot RL. SHP2 inhibition enhances Yes-associated protein-mediated liver regeneration in murine partial hepatectomy models. JCI Insight. 2022 Aug 8; 7 (15) Epub 2022 Aug 08
    View PubMed
  38. Uson Junior PLS, DeLeon TT, Bogenberger JM, Pai RK, Kosiorek HE, Yin J, Ahn DH, Sonbol MB, Bekaii-Saab T, Mansfield AS, Buetow K, Gores GJ, Smoot R, Vasmatzis G, Kipp BR, Mahipal A, Baker AT, Babiker H, Barro O, Dumbauld C, Zhou Y, Aslam FN, Barrett M, Jacobs B, Meurice N, Arora M, Petit J, Elliott N, Nagalo B, Salomao MA, Borad MJ. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Dig Dis Sci. 2022 Aug; 67(8):3797-3805. Epub 2021 Nov 13.
    View PubMed
  39. Uson Junior PLS, Majeed U, Yin J, Botrus G, Sonbol MB, Ahn DH, Starr JS, Jones JC, Babiker H, Inabinett SR, Wylie N, Boyle AWR, Bekaii-Saab TS, Gores GJ, Smoot R, Barrett M, Nagalo B, Meurice N, Elliott N, Petit J, Zhou Y, Arora M, Dumbauld C, Barro O, Baker A, Bogenberger J, Buetow K, Mansfield A, Mody K, Borad MJ. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precis Oncol. 2022 Jun; 6 (1):e2100274
    View PubMed
  40. Walker DI, Juran BD, Cheung AC, Schlicht EM, Liang Y, Niedzwiecki M, LaRusso NF, Gores GJ, Jones DP, Miller GW, Lazaridis KN. High-Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases. Hepatol Commun. 2022 May; 6 (5):965-979 Epub 2021 Nov 26
    View PubMed
  41. Baroud S, Sahakian AJ, Sawas T, Storm AC, Martin JA, Abu Dayyeh BK, Topazian MD, Levy MJ, Roberts LR, Gores GJ, Petersen BT, Chandrasekhara V. Impact of trimodality sampling on detection of malignant biliary strictures compared with patients with primary sclerosing cholangitis. Gastrointest Endosc. 2022 May; 95 (5):884-892 Epub 2021 Dec 03
    View PubMed
  42. Meng XW, Peterson KL, Dai H, Schneider P, Lee SH, Zhang JS, Koenig A, Bronk S, Billadeau DD, Gores GJ, Kaufmann SH. Correction: High cell surface death receptor expression determines type I versus type II signaling. J Biol Chem. 2022 May; 298 (5):101980 Epub 2022 Apr 28
    View PubMed
  43. Miyabe K, Chandrasekhara V, Wongjarupong N, Chen J, Yang L, Johnson S, Chia N, Walther-Antonio M, Yao JZ, Harrington SC, Nordyke CK, Eaton JE, Gossard AA, Oli S, Ali HA, Lavu S, Giama NH, Hassan FA, Ali HM, Enders FT, Ilyas SI, Gores GJ, Topazian MD, Kashyap PC, Roberts LR. Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma. Cancers (Basel). 2022 Apr 24; 14 (9)
    View PubMed
  44. Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ, Villanueva A. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022 Apr; 3 (4):386-401 Epub 2022 Apr 28
    View PubMed
  45. Cheung AC, Juran BD, Schlicht EM, McCauley BM, Atkinson EJ, Moore R, Heimbach JK, Watt KD, Wu TT, LaRusso NF, Gores GJ, Sun Z, Lazaridis KN. DNA methylation profile of liver tissue in end-stage cholestatic liver disease. Epigenomics. 2022 Apr; 14 (8):481-497 Epub 2022 Apr 27
    View PubMed
  46. Eaton JE, Haseeb A, Rupp C, Eusebi LH, van Munster K, Voitl R, Thorburn D, Ponsioen CY, Enders FT, Petersen BT, Abu Dayyeh BK, Baron TH, Chandrasekhara V, Gostout CJ, Levy MJ, Martin J, Storm AC, Dierkhising R, Kamath PS, Gores GJ, Topazian M. Predictors of Jaundice Resolution and Survival After Endoscopic Treatment of Primary Sclerosing Cholangitis. Hepatol Commun. 2022 Apr; 6 (4):809-820 Epub 2021 Sept 01
    View PubMed
  47. Chumsri S, Advani PP, Pai TS, Li Z, Mummareddy A, Acampora M, Reynolds GA, Wylie N, Boyle AW, Lou Y, Mody K, Moreno-Aspitia A, Swift MD, Virk A, Bharucha AE, Marquez CP, Patel TC, Gores GJ, Knutson KL. Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients. Mayo Clin Proc Innov Qual Outcomes. 2022 Apr; 6 (2):120-125 Epub 2021 Dec 13
    View PubMed
  48. Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, Bekaii-Saab T, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Invest New Drugs. 2022 Feb; 40 (1):134-141 Epub 2021 Aug 31
    View PubMed
  49. Yang Z, Zhang T, Kusumanchi P, Tang Q, Sun Z, Radaeva S, Peiffer B, Shah VH, Kamath P, Gores GJ, Sanyal A, Chalasani N, Jiang Y, Huda N, Ma J, Liangpunsakul S. Transcriptomic Analysis Reveals the MicroRNAs Responsible for Liver Regeneration Associated With Mortality in Alcohol-Associated Hepatitis. Hepatology. 2021 Nov; 74 (5):2436-2451 Epub 2021 July 26
    View PubMed
  50. Lee YT, Wang JJ, Luu M, Noureddin M, Nissen NN, Patel TC, Roberts LR, Singal AG, Gores GJ, Yang JD. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. Hepatology. 2021 Nov; 74 (5):2622-2632 Epub 2021 Sept 25
    View PubMed
  51. Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 Nov; 161 (5):1475-1486 Epub 2021 July 23
    View PubMed
  52. Mueller M, Breuer E, Mizuno T, Bartsch F, Ratti F, Benzing C, Ammar-Khodja N, Sugiura T, Takayashiki T, Hessheimer A, Kim HS, Ruzzenente A, Ahn KS, Wong T, Bednarsch J, D'Silva M, Koerkamp BG, Jeddou H, Lopez-Lopez V, de Ponthaud C, Yonkus JA, Ismail W, Nooijen LE, Hidalgo-Salinas C, Kontis E, Wagner KC, Gunasekaran G, Higuchi R, Gleisner A, Shwaartz C, Sapisochin G, Schulick RD, Yamamoto M, Noji T, Hirano S, Schwartz M, Oldhafer KJ, Prachalias A, Fusai GK, Erdmann JI, Line PD, Smoot RL, Soubrane O, Robles-Campos R, Boudjema K, Polak WG, Han HS, Neumann UP, Lo CM, Kang KJ, Guglielmi A, Park JS, Fondevila C, Ohtsuka M, Uesaka K, Adam R, Pratschke J, Aldrighetti L, De Oliveira ML, Gores GJ, Lang H, Nagino M, Clavien PA. Perihilar Cholangiocarcinoma - Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers. Ann Surg. 2021 Nov 1; 274 (5):780-788
    View PubMed
  53. Corchado-Garcia J, Zemmour D, Hughes T, Bandi H, Cristea-Platon T, Lenehan P, Pawlowski C, Bade S, O'Horo JC, Gores GJ, Williams AW, Badley AD, Halamka J, Virk A, Swift MD, Wagner T, Soundararajan V. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19. JAMA Netw Open. 2021 Nov 1; 4 (11):e2132540 Epub 2021 Nov 01
    View PubMed
  54. Pawlowski C, Rincon-Hekking J, Awasthi S, Pandey V, Lenehan P, Venkatakrishnan AJ, Bade S, O'Horo JC, Virk A, Swift MD, Williams AW, Gores GJ, Badley AD, Halamka J, Soundararajan V. Cerebral Venous Sinus Thrombosis is not Significantly Linked to COVID-19 Vaccines or Non-COVID Vaccines in a Large Multi-State Health System. J Stroke Cerebrovasc Dis. 2021 Oct; 30 (10):105923 Epub 2021 June 16
    View PubMed
  55. Wang J, Loeuillard E, Gores GJ, Ilyas SI. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells? Expert Opin Ther Targets. 2021 Oct; 25 (10):835-845 Epub 2021 Dec 03
    View PubMed
  56. Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S, Gores GJ. Cholangiocarcinoma. Nat Rev Dis Primers. 2021 Sep 9; 7 (1):65 Epub 2021 Sept 09
    View PubMed
  57. McMurry R, Lenehan P, Awasthi S, Silvert E, Puranik A, Pawlowski C, Venkatakrishnan AJ, Anand P, Agarwal V, O'Horo JC, Gores GJ, Williams AW, Badley AD, Halamka J, Virk A, Swift MD, Carlson K, Doddahonnaiah D, Metzger A, Kayal N, Berner G, Ramudu E, Carpenter C, Wagner T, Rajasekharan A, Soundararajan V. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med (N Y). 2021 Aug 13; 2 (8):965-978.e5 Epub 2021 July 01
    View PubMed
  58. Yang JD, Ghoz H, Aboelsoud MM, Taylor WR, Yab TC, Berger CK, Cao X, Foote PH, Giama NH, Barr Fritcher EG, Mahoney DW, Moser CD, Smyrk TC, Kipp BR, Gores GJ, Roberts LR, Kisiel JB. DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. Hepatol Commun. 2021 Aug; 5 (8):1448-1459 Epub 2021 May 03
    View PubMed
  59. Mousa OY, Juran BD, McCauley BM, Vesterhus MN, Folseraas T, Turgeon CT, Ali AH, Schlicht EM, Atkinson EJ, Hu C, Harnois D, Carey EJ, Gossard AA, Oglesbee D, Eaton JE, LaRusso NF, Gores GJ, Karlsen TH, Lazaridis KN. Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. Hepatology. 2021 Jul; 74 (1):281-295 Epub 2021 June 15
    View PubMed
  60. Hirsova P, Gores GJ. Fatty liver progression and carcinogenesis: Beware of pathogenic T cells. Med (N Y) 2021 May 14; 2 (5):453-455
    View PubMed
  61. Diggs LP, Ruf B, Ma C, Heinrich B, Cui L, Zhang Q, McVey JC, Wabitsch S, Heinrich S, Rosato U, Lai W, Subramanyam V, Longerich T, Loosen SH, Luedde T, Neumann UP, Desar S, Kleiner D, Gores G, Wang XW, Greten TF. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. J Hepatol. 2021 May; 74 (5):1145-1154 Epub 2020 Dec 01
    View PubMed
  62. Eaton JE, Welle CL, Bakhshi Z, Sheedy SP, Idilman IS, Gores GJ, Rosen CB, Heimbach JK, Taner T, Harnois DM, Lindor KD, LaRusso NF, Gossard AA, Lazaridis KN, Venkatesh SK. Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. Hepatology. 2021 May; 73 (5):1868-1881 Epub 2021 Apr 19
    View PubMed
  63. Awasthi S, Wagner T, Venkatakrishnan AJ, Puranik A, Hurchik M, Agarwal V, Conrad I, Kirkup C, Arunachalam R, O'Horo J, Kremers W, Kashyap R, Morice W 2nd, Halamka J, Williams AW, Faubion WA Jr, Badley AD, Gores GJ, Soundararajan V. Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients. Cell Death Discov. 2021 Mar 15; 7 (1):55
    View PubMed
  64. Pawlowski C, Puranik A, Bandi H, Venkatakrishnan AJ, Agarwal V, Kennedy R, O'Horo JC, Gores GJ, Williams AW, Halamka J, Badley AD, Soundararajan V. Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations. Sci Rep. 2021 Feb 26; 11 (1):4741
    View PubMed
  65. Sehrawat TS, Arab JP, Liu M, Amrollahi P, Wan M, Fan J, Nakao Y, Pose E, Navarro-Corcuera A, Dasgupta D, Liao CY, He L, Mauer AS, Avitabile E, Ventura-Cots M, Bataller RA, Sanyal AJ, Chalasani NP, Heimbach JK, Watt KD, Gores GJ, Gines P, Kamath PS, Simonetto DA, Hu TY, Shah VH, Malhi H. Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. Hepatology. 2021 Feb; 73 (2):571-585 Epub 2020 Oct 30
    View PubMed
  66. Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol. 2021; 5 Epub 2021 July 28
    View PubMed
  67. He L, Sehrawat TS, Verma VK, Navarro-Corcuera A, Sidhu G, Mauer A, Luo X, Katsumi T, Chen J, Shah S, Arab JP, Cao S, Kashkar H, Gores GJ, Malhi H, Shah VH. XIAP Knockdown in Alcohol-Associated Liver Disease Models Exhibits Divergent in vitro and in vivo Phenotypes Owing to a Potential Zonal Inhibitory Role of SMAC. Front Physiol. 2021; 12:664222 Epub 2021 May 07
    View PubMed
  68. Gores GJ, McNiven MA, Roberts LR. The Difference a Decade Makes. Hepatology. 2021 Jan; 73 Suppl 1:1-3
    View PubMed
  69. Tse CS, Yang JD, Mousa OY, Nelson KM, Pungpapong S, Keaveny A, Aqel BA, Vargas H, Dickson RC, Watt K, Gores GJ, Roberts LR, Leise MD. Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. Transplant Direct. 2021 Jan; 7(1):e635. Epub 2020 Dec 08.
    View PubMed
  70. Agarwal V, Venkatakrishnan AJ, Puranik A, Kirkup C, Lopez-Marquez A, Challener DW, Theel ES, O'Horo JC, Binnicker MJ, Kremers WK, Faubion WA Jr, Badley AD, Williams AW, Gores GJ, Halamka JD, Morice WG 2nd, Soundararajan V. Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity. Cell Death Discov. 2020 Dec 2; 6 (1):138 Epub 2020 Dec 02
    View PubMed
  71. Tan EK, Taner T, Heimbach JK, Gores GJ, Rosen CB. Liver Transplantation for Peri-hilar Cholangiocarcinoma. J Gastrointest Surg. 2020 Nov; 24 (11):2679-2685 Epub 2020 July 15
    View PubMed
  72. Ibrahim SH, Hirsova P, Malhi H, Gores GJ. Nonalcoholic Steatohepatitis Promoting Kinases. Semin Liver Dis. 2020 Nov; 40 (4):346-357 Epub 2020 June 11
    View PubMed
  73. Azad AI, Rosen CB, Taner T, Heimbach JK, Gores GJ. Selected Patients with Unresectable Perihilar Cholangiocarcinoma (pCCA) Derive Long-Term Benefit from Liver Transplantation. Cancers (Basel). 2020 Oct 27; 12 (11)
    View PubMed
  74. Vunnam N, Szymonski S, Hirsova P, Gores GJ, Sachs JN, Hackel BJ. Noncompetitive Allosteric Antagonism of Death Receptor 5 by a Synthetic Affibody Ligand. Biochemistry. 2020 Oct 13; 59 (40):3856-3868 Epub 2020 Sept 30
    View PubMed
  75. Gammon ST, Engel BJ, Gores GJ, Cressman E, Piwnica-Worms D, Millward SW. Mistiming Death: Modeling the Time-Domain Variability of Tumor Apoptosis and Implications for Molecular Imaging of Cell Death. Mol Imaging Biol. 2020 Oct; 22 (5):1310-1323
    View PubMed
  76. Pitzen JH, Dieter HL, Gronseth DL, Dahl AK, Boyle VL, Maran T, Harper CM Jr, Gores GJ. Transforming the practice of medicine through team science. Health Res Policy Syst. 2020 Sep 17; 18 (1):104 Epub 2020 Sept 17
    View PubMed
  77. Azad AI, Krishnan A, Troop L, Li Y, Katsumi T, Pavelko K, Kostallari E, Guicciardi ME, Gores GJ. Targeted Apoptosis of Ductular Reactive Cells Reduces Hepatic Fibrosis in a Mouse Model of Cholestasis. Hepatology. 2020 Sep; 72 (3):1013-1028
    View PubMed
  78. Kim TH, Banini BA, Asumda FZ, Campbell NA, Hu C, Moser CD, Shire AM, Han S, Ma C, Krishnan A, Mounajjed T, White TA, Gores GJ, LeBrasseur NK, Charlton MR, Roberts LR. Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol. 2020 Sep 01; 319(3):G333-G344. Epub 2020 Jul 20.
    View PubMed
  79. Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020 Sep; 17 (9):557-588 Epub 2020 June 30
    View PubMed
  80. Malikowski T, Levy MJ, Gleeson FC, Storm AC, Vargas EJ, Topazian MD, Abu Dayyeh BK, Iyer PG, Rajan E, Gores GJ, Roberts LR, Chandrasekhara V. Endoscopic Ultrasound/Fine Needle Aspiration Is Effective for Lymph Node Staging in Patients With Cholangiocarcinoma. Hepatology. 2020 Sep; 72 (3):940-948 Epub 2020 July 09
    View PubMed
  81. Pawlowski C, Wagner T, Puranik A, Murugadoss K, Loscalzo L, Venkatakrishnan AJ, Pruthi RK, Houghton DE, O'Horo JC, Morice WG 2nd, Williams AW, Gores GJ, Halamka J, Badley AD, Barnathan ES, Makimura H, Khan N, Soundararajan V. Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC). Elife. 2020 Aug 17; 9
    View PubMed
  82. Gautheron J, Gores GJ, Rodrigues CMP. Lytic cell death in metabolic liver disease. J Hepatol. 2020 Aug; 73 (2):394-408 Epub 2020 Apr 13
    View PubMed
  83. Fabris L, Cadamuro M, Cagnin S, Strazzabosco M, Gores GJ. Liver Matrix in Benign and Malignant Biliary Tract Disease. Semin Liver Dis. 2020 Aug; 40 (3):282-297 Epub 2020 Mar 11
    View PubMed
  84. Arab JP, Sehrawat TS, Simonetto DA, Verma VK, Feng D, Tang T, Dreyer K, Yan X, Daley WL, Sanyal A, Chalasani N, Radaeva S, Yang L, Vargas H, Ibacache M, Gao B, Gores GJ, Malhi H, Kamath PS, Shah VH. An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis. Hepatology. 2020 Aug; 72 (2):441-453 Epub 2020 Apr 27
    View PubMed
  85. Wagner T, Shweta F, Murugadoss K, Awasthi S, Venkatakrishnan AJ, Bade S, Puranik A, Kang M, Pickering BW, O'Horo JC, Bauer PR, Razonable RR, Vergidis P, Temesgen Z, Rizza S, Mahmood M, Wilson WR, Challener D, Anand P, Liebers M, Doctor Z, Silvert E, Solomon H, Anand A, Barve R, Gores G, Williams AW, Morice WG 2nd, Halamka J, Badley A, Soundararajan V. Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis. Elife. 2020 Jul 7; 9 Epub 2020 July 07
    View PubMed
  86. Tan EK, Rosen CB, Heimbach JK, Gores GJ, Zamora-Valdes D, Taner T. Living Donor Liver Transplantation for Perihilar Cholangiocarcinoma: Outcomes and Complications. J Am Coll Surg. 2020 Jul; 231 (1):98-110 Epub 2020 Feb 06
    View PubMed
  87. Werneburg N, Gores GJ, Smoot RL. The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies. Gene Expr. 2020 Jun 12; 20 (1):67-74 Epub 2019 June 28
    View PubMed
  88. Krishnan A, Katsumi T, Guicciardi ME, Azad AI, Ozturk NB, Trussoni CE, Gores GJ. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Deficiency Promotes the Ductular Reaction, Macrophage Accumulation, and Hepatic Fibrosis in the Abcb4(-/-) Mouse. Am J Pathol. 2020 Jun; 190 (6):1284-1297 Epub 2020 Mar 30
    View PubMed
  89. Eaton JE, Sen A, Hoodeshenas S, Schleck CD, Harmsen WS, Gores GJ, LaRusso NF, Gossard AA, Lazaridis KN, Venkatesh SK. Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2020 Jun; 18 (7):1576-1583.e1 Epub 2019 Nov 01
    View PubMed
  90. Roddy GW, Rosa RH, Viker KB, Holman BH, Hann CR, Krishnan A, Gores GJ, Bakri SJ, Fautsch MP. Diet Mimicking "Fast Food" Causes Structural Changes to the Retina Relevant to Age-Related Macular Degeneration. Curr Eye Res. 2020 Jun; 45 (6):726-732 Epub 2019 Dec 02
    View PubMed
  91. Bakhshi Z, Hilscher MB, Gores GJ, Harmsen WS, Viehman JK, LaRusso NF, Gossard AA, Lazaridis KN, Lindor KD, Eaton JE. An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. J Gastroenterol. 2020 May; 55 (5):523-532 Epub 2020 Jan 13
    View PubMed
  92. Kaura K, Sawas T, Bazerbachi F, Storm AC, Martin JA, Gores GJ, Abu Dayyeh BK, Topazian MD, Levy MJ, Petersen BT, Chandrasekhara V. Cholangioscopy Biopsies Improve Detection of Cholangiocarcinoma When Combined with Cytology and FISH, but Not in Patients with PSC. Dig Dis Sci. 2020 May; 65 (5):1471-1478 Epub 2019 Sept 30
    View PubMed
  93. Leiting JL, Murphy SJ, Bergquist JR, Hernandez MC, Ivanics T, Abdelrahman AM, Yang L, Lynch I, Smadbeck JB, Cleary SP, Nagorney DM, Torbenson MS, Graham RP, Roberts LR, Gores GJ, Smoot RL, Truty MJ. Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine. JHEP Rep. 2020 Apr; 2 (2):100068 Epub 2020 Jan 16
    View PubMed
  94. Taner T, Abrol N, Park WD, Hansen MJ, Gustafson MP, Lerman LO, van Wijnen AJ, Dietz AB, Gores GJ, Stegall MD. Phenotypic, Transcriptional, and Functional Analysis of Liver Mesenchymal Stromal Cells and Their Immunomodulatory Properties. Liver Transpl. 2020 Apr; 26 (4):549-563 Epub 2020 Mar 04
    View PubMed
  95. Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR. Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. Hepatology. 2020 Mar; 71 (3):907-916 Epub 2019 Oct 21
    View PubMed
  96. Rizvi S, Gores GJ. The Two Faces of Relaxin in Cancer: Antitumor or Protumor? Hepatology 2020 Mar; 71 (3):1117-1119
    View PubMed
  97. Hirsova P, Bohm F, Dohnalkova E, Nozickova B, Heikenwalder M, Gores GJ, Weber A. Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis. Cell Death Dis. 2020 Feb 3; 11 (2):80 Epub 2020 Feb 03
    View PubMed
  98. Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020 Feb; 72 (2):353-363
    View PubMed
  99. Guicciardi ME, Trussoni CE, LaRusso NF, Gores GJ. The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis. Hepatology. 2020 Feb; 71 (2):741-748
    View PubMed
  100. Eaton JE, Vesterhus M, McCauley BM, Atkinson EJ, Schlicht EM, Juran BD, Gossard AA, LaRusso NF, Gores GJ, Karlsen TH, Lazaridis KN. Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. Hepatology. 2020 Jan; 71 (1):214-224 Epub 2018 Dec 28
    View PubMed
  101. Cadamuro M, Girardi N, Gores GJ, Strazzabosco M, Fabris L. The Emerging Role of Macrophages in Chronic Cholangiopathies Featuring Biliary Fibrosis: An Attractive Therapeutic Target for Orphan Diseases. Front Med (Lausanne). 2020; 7:115 Epub 2020 Apr 21
    View PubMed
  102. O'Hara SP, Splinter PL, Trussoni CE, Guicciardi ME, Splinter NP, Al Suraih MS, Nasser-Ghodsi N, Stollenwerk D, Gores GJ, LaRusso NF. The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1. J Biol Chem. 2019 Dec 6; 294 (49):18698-18713 Epub 2019 Oct 28
    View PubMed
  103. Katsumi T, Guicciardi ME, Azad A, Bronk SF, Krishnan A, Gores GJ. Activated cholangiocytes release macrophage-polarizing extracellular vesicles bearing the DAMP S100A11. Am J Physiol Cell Physiol. 2019 Oct 1; 317 (4):C788-C799 Epub 2019 July 31
    View PubMed
  104. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019 Oct; 16 (10):589-604 Epub 2019 Aug 22
    View PubMed
  105. Loeuillard E, Conboy CB, Gores GJ, Rizvi S. Immunobiology of cholangiocarcinoma. JHEP Rep. 2019 Oct; 1 (4):297-311 Epub 2019 July 10
    View PubMed
  106. Aziz K, Limzerwala JF, Sturmlechner I, Hurley E, Zhang C, Jeganathan KB, Nelson G, Bronk S, Fierro Velasco RO, van Deursen EJ, O'Brien DR, Kocher JA, Youssef SA, van Ree JH, de Bruin A, van den Bos H, Spierings DCJ, Foijer F, van de Sluis B, Roberts LR, Gores GJ, Li H, van Deursen JM. Ccne1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice. Gastroenterology. 2019 Jul; 157 (1):210-226.e12 Epub 2019 Mar 13
    View PubMed
  107. Sugihara T, Isomoto H, Gores G, Smoot R. YAP and the Hippo pathway in cholangiocarcinoma. J Gastroenterol. 2019 Jun; 54 (6):485-491 Epub 2019 Feb 27
    View PubMed
  108. Eaton JE, Gores GJ. Long-term outcomes with obeticholic acid in primary biliary cholangitis: reassuring, but still an itch we need to scratch. Lancet Gastroenterol Hepatol 2019 Jun; 4 (6):417-418 Epub 2019 Mar 26
    View PubMed
  109. Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019 May; 16 (5):269-281
    View PubMed
  110. Loeuillard E, Fischbach SR, Gores GJ, Ilyas SI. Animal models of cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2019 May 1; 1865 (5):982-992 Epub 2018 Apr 05
    View PubMed
  111. Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wei Wang X, Zhu AX. Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. Hepatology. 2019 Apr; 69 (4):1803-1815 Epub 2019 Mar 25
    View PubMed
  112. Anderson JR, Chung TDY, Clark L, Weis JA, Danielsen AJ, Khosla S, Gores GJ, Badley AD. Translation to Practice: Accelerating the Cycle of Innovation to Impact. Mayo Clin Proc. 2019 Mar; 94 (3):490-499 Epub 2019 Feb 07
    View PubMed
  113. Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, Zhang N, Wongjarupong N, Ali HM, Ali HA, Hassan FA, Lavu S, Cvinar JL, Giama NH, Moser CD, Miyabe K, Allotey LK, Algeciras-Schimnich A, Theobald JP, Ward MM, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Srivastava S, Rinaudo JA, Gores GJ, Feng Z, Marrero JA, Roberts LR. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2019 Mar; 28 (3):531-538 Epub 2018 Nov 21
    View PubMed
  114. Razumilava N, Shiota J, Mohamad Zaki NH, Ocadiz-Ruiz R, Cieslak CM, Zakharia K, Allen BL, Gores GJ, Samuelson LC, Merchant JL. Hedgehog Signaling Modulates Interleukin-33-Dependent Extrahepatic Bile Duct Cell Proliferation in Mice. Hepatol Commun. 2019 Feb; 3 (2):277-292 Epub 2018 Dec 11
    View PubMed
  115. Rizvi S, Gores GJ. Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened. Hepatology 2018 Dec; 68 (6):2428-2430 Epub 2018 Nov 07
    View PubMed
  116. Sugihara T, Werneburg NW, Hernandez MC, Yang L, Kabashima A, Hirsova P, Yohanathan L, Sosa C, Truty MJ, Vasmatzis G, Gores GJ, Smoot RL. YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res. 2018 Oct; 16 (10):1556-1567 Epub 2018 June 14
    View PubMed
  117. Guicciardi ME, Trussoni CE, Krishnan A, Bronk SF, Lorenzo Pisarello MJ, O'Hara SP, Splinter PL, Gao Y, Vig P, Revzin A, LaRusso NF, Gores GJ. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol. 2018 Sep; 69 (3):676-686 Epub 2018 May 24
    View PubMed
  118. Yang JD, Mannalithara A, Piscitello AJ, Kisiel JB, Gores GJ, Roberts LR, Kim WR. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology. 2018 Jul; 68 (1):78-88 Epub 2018 May 09
    View PubMed
  119. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, Kondo F, Miksad R, Nakano M, Nakanuma Y, Ng I, Paradis V, Nyun Park Y, Quaglia A, Roncalli M, Roskams T, Sakamoto M, Saxena R, Sempoux C, Sirlin C, Stueck A, Thung S, Tsui WMS, Wang XW, Wee A, Yano H, Yeh M, Zen Y, Zucman-Rossi J, Theise N. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology. 2018 Jul; 68 (1):113-126 Epub 2018 May 09
    View PubMed
  120. Kabashima A, Hirsova P, Bronk SF, Hernandez MC, Truty MJ, Ilyas SI, Kaufmann SH, Gores GJ. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. J Hepatol. 2018 Jun; 68 (6):1228-1238 Epub 2018 Mar 09
    View PubMed
  121. Ibrahim SH, Hirsova P, Gores GJ. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut. 2018 May; 67 (5):963-972 Epub 2018 Jan 24
    View PubMed
  122. Rizvi S, I Ilyas S, Eaton J, Yang JD, Chandrasekhara V, Gores GJ. Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. Semin Liver Dis. 2018 May; 38 (2):160-169 Epub 2018 June 05
    View PubMed
  123. Puri P, Liangpunsakul S, Christensen JE, Shah VH, Kamath PS, Gores GJ, Walker S, Comerford M, Katz B, Borst A, Yu Q, Kumar DP, Mirshahi F, Radaeva S, Chalasani NP, Crabb DW, Sanyal AJ, TREAT Consortium. The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. Hepatology. 2018 Apr; 67 (4):1284-1302 Epub 2018 Feb 22
    View PubMed
  124. Mertens JC, Ilyas SI, Gores GJ. Targeting cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018 Apr; 1864 (4 Pt B):1454-1460 Epub 2017 Aug 24
    View PubMed
  125. Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Feb; 15 (2):95-111 Epub 2017 Oct 10
    View PubMed
  126. Rizvi S, Fischbach SR, Bronk SF, Hirsova P, Krishnan A, Dhanasekaran R, Smadbeck JB, Smoot RL, Vasmatzis G, Gores GJ. YAP-associated chromosomal instability and cholangiocarcinoma in mice. Oncotarget. 2018 Jan 19; 9 (5):5892-5905 Epub 2017 Dec 22
    View PubMed
  127. Moncsek A, Al-Suraih MS, Trussoni CE, O'Hara SP, Splinter PL, Zuber C, Patsenker E, Valli PV, Fingas CD, Weber A, Zhu Y, Tchkonia T, Kirkland JL, Gores GJ, Müllhaupt B, LaRusso NF, Mertens JC. Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice. Hepatology. 2018 Jan; 67(1):247-259. Epub 2017 Nov 29.
    View PubMed
  128. Smoot RL, Werneburg NW, Sugihara T, Hernandez MC, Yang L, Mehner C, Graham RP, Bronk SF, Truty MJ, Gores GJ. Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation. J Cell Biochem. 2018 Jan; 119 (1):824-836 Epub 2017 Aug 03
    View PubMed
  129. Gossard AA, Gores GJ. Primary Sclerosing Cholangitis: What the Gastroenterologist and Hepatologist Needs to Know. Clin Liver Dis. 2017 Nov; 21 (4):725-737 Epub 2017 July 25
    View PubMed
  130. Loarca L, De Assuncao TM, Jalan-Sakrikar N, Bronk S, Krishnan A, Huang B, Morton L, Trussoni C, Bonilla LM, Krueger E, O'Hara S, Splinter P, Shi G, Pisarello MJL, Gores GJ, Huebert RC, LaRusso NF. Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis. Lab Invest. 2017 Nov; 97 (11):1385-1396 Epub 2017 Sept 11
    View PubMed
  131. Gossard AA, Gores GJ. PPAR agonists for primary biliary cholangitis. Lancet Gastroenterol Hepatol 2017 Oct; 2 (10):693-694 Epub 2017 Aug 14
    View PubMed
  132. Greuter T, Malhi H, Gores GJ, Shah VH. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight. 2017 Sep 7; 2 (17) Epub 2017 Sept 07
    View PubMed
  133. Yang JD, Ahmed Mohammed H, Harmsen WS, Enders F, Gores GJ, Roberts LR. Recent Trends in the Epidemiology of Hepatocellular Carcinoma in Olmsted County, Minnesota: A US Population-based Study. J Clin Gastroenterol. 2017 Sep; 51 (8):742-748
    View PubMed
  134. Hirsova P, Weng P, Salim W, Bronk SF, Griffith TS, Ibrahim SH, Gores GJ. TRAIL Deletion Prevents Liver, but Not Adipose Tissue, Inflammation during Murine Diet-Induced Obesity. Hepatol Commun. 2017 Sep; 1 (7):648-662 Epub 2017 July 20
    View PubMed
  135. Ilyas SI, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol. 2017 Sep; 67 (3):632-644 Epub 2017 Apr 05
    View PubMed
  136. Liu Y, Verma VK, Malhi H, Gores GJ, Kamath PS, Sanyal A, Chalasani N, Gao B, Shah VH. Lipopolysaccharide downregulates macrophage-derived IL-22 to modulate alcohol-induced hepatocyte cell death. Am J Physiol Cell Physiol. 2017 Sep 1; 313 (3):C305-C313 Epub 2017 June 21
    View PubMed
  137. Bhat M, Yanagiya A, Graber T, Razumilava N, Bronk S, Zammit D, Zhao Y, Zakaria C, Metrakos P, Pollak M, Sonenberg N, Gores G, Jaramillo M, Morita M, Alain T. Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. Oncotarget. 2017 Aug 1; 8 (31):50542-50556 Epub 2016 July 18
    View PubMed
  138. Ramanan P, Cummins NW, Wilhelm MP, Heimbach JK, Dierkhising R, Kremers WK, Rosen CB, Gores GJ, Razonable RR. Epidemiology, risk factors, and outcomes of infections in patients undergoing liver transplantation for hilar cholangiocarcinoma. Clin Transplant. 2017 Aug; 31 (8) Epub 2017 July 05
    View PubMed
  139. Yang JD, Dai J, Singal AG, Gopal P, Addissie BD, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Gores GJ, Feng Z, Marrero JA, Roberts LR. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. Cancer Epidemiol Biomarkers Prev. 2017 Jul; 26 (7):1085-1092 Epub 2017 Mar 03
    View PubMed
  140. Merino-Azpitarte M, Lozano E, Perugorria MJ, Esparza-Baquer A, Erice O, Santos-Laso A, O'Rourke CJ, Andersen JB, Jimenez-Aguero R, Lacasta A, D'Amato M, Briz O, Jalan-Sakrikar N, Huebert RC, Thelen KM, Gradilone SA, Aransay AM, Lavin JL, Fernandez-Barrena MG, Matheu A, Marzioni M, Gores GJ, Bujanda L, Marin JJG, Banales JM. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. J Hepatol. 2017 Jul; 67 (1):72-83 Epub 2017 Feb 22
    View PubMed
  141. Lourens S, Sunjaya DB, Singal A, Liangpunsakul S, Puri P, Sanyal A, Ren X, Gores GJ, Radaeva S, Chalasani N, Crabb DW, Katz B, Kamath PS, Shah VH, TREAT Consortium. Acute Alcoholic Hepatitis: Natural History and Predictors of Mortality Using a Multicenter Prospective Study. Mayo Clin Proc Innov Qual Outcomes. 2017 Jul; 1 (1):37-48 Epub 2017 Apr 28
    View PubMed
  142. Krishnan A, Abdullah TS, Mounajjed T, Hartono S, McConico A, White T, LeBrasseur N, Lanza I, Nair S, Gores G, Charlton M. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2017 Jun 1; 312 (6):G666-G680 Epub 2017 Feb 23
    View PubMed
  143. Cheung AC, Lazaridis KN, LaRusso NF, Gores GJ. Emerging pharmacologic therapies for primary sclerosing cholangitis. Curr Opin Gastroenterol. 2017 May; 33 (3):149-157
    View PubMed
  144. Yang JD, Larson JJ, Watt KD, Allen AM, Wiesner RH, Gores GJ, Roberts LR, Heimbach JA, Leise MD. Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. Clin Gastroenterol Hepatol. 2017 May; 15 (5):767-775.e3 Epub 2016 Dec 21
    View PubMed
  145. Cheung AC, LaRusso NF, Gores GJ, Lazaridis KN. Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Semin Liver Dis. 2017 May; 37 (2):159-174 Epub 2017 May 31
    View PubMed
  146. Fan W, Yang H, Liu T, Wang J, Li TW, Mavila N, Tang Y, Yang J, Peng H, Tu J, Annamalai A, Noureddin M, Krishnan A, Gores GJ, Martinez-Chantar ML, Mato JM, Lu SC. Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells. Hepatology. 2017 Apr; 65 (4):1249-1266 Epub 2017 Jan 31
    View PubMed
  147. Yang JD, Mohamed EA, Aziz AO, Shousha HI, Hashem MB, Nabeel MM, Abdelmaksoud AH, Elbaz TM, Afihene MY, Duduyemi BM, Ayawin JP, Gyedu A, Lohoues-Kouacou MJ, Ndam AW, Moustafa EF, Hassany SM, Moussa AM, Ugiagbe RA, Omuemu CE, Anthony R, Palmer D, Nyanga AF, Malu AO, Obekpa S, Abdo AE, Siddig AI, Mudawi HM, Okonkwo U, Kooffreh-Ada M, Awuku YA, Nartey YA, Abbew ET, Awuku NA, Otegbayo JA, Akande KO, Desalegn HM, Omonisi AE, Ajayi AO, Okeke EN, Duguru MJ, Davwar PM, Okorie MC, Mustapha S, Debes JD, Ocama P, Lesi OA, Odeghe E, Bello R, Onyekwere C, Ekere F, Igetei R, Mah'moud MA, Addissie B, Ali HM, Gores GJ, Topazian MD, Roberts LR, Africa Network for Gastrointestinal and Liver Diseases. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017 Feb; 2 (2):103-111 Epub 2016 Dec 03
    View PubMed
  148. Guicciardi ME, Krishnan A, Bronk SF, Hirsova P, Griffith TS, Gores GJ. Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice. Cell Death Dis. 2017 Jan 5; 8 (1):e2535 Epub 2017 Jan 05
    View PubMed
  149. Rizvi S, Yang JD, Gores GJ. Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis? Gut 2017 Jan; 66 (1):4-5 Epub 2016 Sept 01
    View PubMed
  150. Yang JD, Altekruse SF, Nguyen MH, Gores GJ, Roberts LR. Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. Cancer. 2017 Jan 1; 123 (1):81-89 Epub 2016 Aug 29
    View PubMed
  151. Hirsova P, Ibrahim SH, Verma VK, Morton LA, Shah VH, LaRusso NF, Gores GJ, Malhi H. Extracellular vesicles in liver pathobiology: Small particles with big impact. Hepatology. 2016 Dec; 64 (6):2219-2233 Epub 2016 Oct 20
    View PubMed
  152. Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016 Dec; 7 (6):819-827
    View PubMed
  153. Yang JD, Mohamed HA, Ahmed Mohammed H, Cvinar JL, Gores GJ, Roberts LR, Kim WR. Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. Am J Gastroenterol. 2016 Nov; 111 (11):1573-1580 Epub 2016 Aug 16
    View PubMed
  154. Razumilava N, Gores GJ. Vigilancia del colangiocarcinoma en pacientes con colangitis esclerosante primaria: inverted question markes efectiva y esta justificada? Clin Liver Dis (Hoboken). 2016 Nov; 8 (Suppl 1):S20-S24 Epub 2016 Nov 10
    View PubMed
  155. Hirsova P, Ibrahim SH, Ibrabim SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J Lipid Res. 2016 Oct; 57 (10):1758-1770 Epub 2016 Apr 05
    View PubMed
  156. Bergquist JR, Ivanics T, Storlie CB, Groeschl RT, Tee MC, Habermann EB, Smoot RL, Kendrick ML, Farnell MB, Roberts LR, Gores GJ, Nagorney DM, Truty MJ. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. J Surg Oncol. 2016 Sep; 114 (4):475-82 Epub 2016 July 20
    View PubMed
  157. Razumilava N, Gores GJ. Surveillance for Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis: Effective and Justified? Clin Liver Dis (Hoboken). 2016 Aug; 8 (2):43-47 Epub 2016 Aug 29
    View PubMed
  158. Yang H, Liu T, Wang J, Li TW, Fan W, Peng H, Krishnan A, Gores GJ, Mato JM, Lu SC. Deregulated methionine adenosyltransferase alpha1, c-Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans(double dagger). Hepatology. 2016 Aug; 64 (2):439-55 Epub 2016 Apr 28
    View PubMed
  159. Rojas A, Zhang P, Wang Y, Foo WC, Munoz NM, Xiao L, Wang J, Gores GJ, Hung MC, Blechacz B. A Positive TGF-beta/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. Neoplasia. 2016 Jun; 18 (6):371-86
    View PubMed
  160. Li L, Che L, Tharp KM, Park HM, Pilo MG, Cao D, Cigliano A, Latte G, Xu Z, Ribback S, Dombrowski F, Evert M, Gores GJ, Stahl A, Calvisi DF, Chen X. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology. 2016 Jun; 63 (6):1900-13 Epub 2016 Mar 25
    View PubMed
  161. Eaton JE, Dzyubak B, Venkatesh SK, Smyrk TC, Gores GJ, Ehman RL, LaRusso NF, Gossard AA, Lazaridis KN. Performance of magnetic resonance elastography in primary sclerosing cholangitis. J Gastroenterol Hepatol. 2016 Jun; 31 (6):1184-90
    View PubMed
  162. Sio TT, Martenson JA Jr, Haddock MG, Novotny PJ, Gores GJ, Alberts SR, Miller RC, Heimbach JK, Rosen CB. Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma. Am J Clin Oncol. 2016 Jun; 39 (3):271-5
    View PubMed
  163. Ibrahim SH, Hirsova P, Malhi H, Gores GJ. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci. 2016 May; 61 (5):1325-36 Epub 2015 Dec 01
    View PubMed
  164. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma Nature Reviews Disease Primers. 2016 Apr 14; 2:16018.
  165. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016 Apr 14; 2:16018
    View PubMed
  166. Ilyas SI, Yamada D, Hirsova P, Bronk SF, Werneburg NW, Krishnan A, Salim W, Zhang L, Trushina E, Truty MJ, Gores GJ. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. J Biol Chem. 2016 Apr 8; 291 (15):8031-47 Epub 2016 Jan 29
    View PubMed
  167. Rizvi S, Gores GJ. Liver capsule: Cholangiocarcinoma (CCA). Hepatology. 2016 Apr; 63 (4):1356 Epub 2016 Feb 01
    View PubMed
  168. Lehrke HD, Heimbach JK, Wu TT, Jenkins SM, Gores GJ, Rosen CB, Mounajjed T. Prognostic Significance of the Histologic Response of Perihilar Cholangiocarcinoma to Preoperative Neoadjuvant Chemoradiation in Liver Explants. Am J Surg Pathol. 2016 Apr; 40: (4)510-8.
    View PubMed
  169. Hirsova P, Ibrahim SH, Krishnan A, Verma VK, Bronk SF, Werneburg NW, Charlton MR, Shah VH, Malhi H, Gores GJ. Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. Gastroenterology. 2016 Apr; 150 (4):956-67 Epub 2016 Jan 05
    View PubMed
  170. Ponsioen CY, Chapman RW, Chazouilleres O, Hirschfield GM, Karlsen TH, Lohse AW, Pinzani M, Schrumpf E, Trauner M, Gores GJ. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology. 2016 Apr; 63: (4)1357-67.
    View PubMed
  171. Rizvi S, Yamada D, Hirsova P, Bronk S, Werneburg NW, Zhang L, Trushina E, Gores GJ. Mo1469 Fibroblast Growth Factor Receptor (FGFR) Signaling Activation Culminates in a Mcl-1 Regulated Tumor Survival Pathway in CC Gastroenterology. 2016; 150(4):S1124.
  172. Verma VK, Li H, Wang R, Hirsova P, Mushref M, Liu Y, Cao S, Contreras PC, Malhi H, Kamath PS, Gores GJ, Shah VH. Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. J Hepatol. 2016 Mar; 64 (3):651-60 Epub 2015 Nov 26
    View PubMed
  173. Ibrahim SH, Hirsova P, Tomita K, Bronk SF, Werneburg NW, Harrison SA, Goodfellow VS, Malhi H, Gores GJ. Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes. Hepatology. 2016 Mar; 63 (3):731-44 Epub 2015 Dec 11
    View PubMed
  174. Bruix J, Gores GJ. Inheriting a Jewel: A Thrilling Challenge. Semin Liver Dis. 2016 Feb; 36: (1)3.
    View PubMed
  175. Shah VH, Gores GJ, LaRusso NF. Hail to the chief-Keith Lindor, our new AASLD president. Hepatology. 2016 Feb; 63 (2):357-9 Epub 2015 Dec 18
    View PubMed
  176. Hirsova P, Ibrabim SH, Gores GJ, Malhi H. Thematic review series: Lipotoxicity: many roads to cell dysfunction and cell death lipotoxic lethal and sublethal stress signaling in hepatocytes: Relevance to NASH pathogenesis Journal of Lipid Research. 2016; 57: (10)1758-70.
  177. Terzic A, Pfenning MA, Gores GJ, Harper CM Jr. Regenerative Medicine Build-Out. Stem Cells Transl Med. 2015 Dec; 4 (12):1373-9 Epub 2015 Nov 04
    View PubMed
  178. Barr Fritcher EG, Voss JS, Brankley SM, Campion MB, Jenkins SM, Keeney ME, Henry MR, Kerr SM, Chaiteerakij R, Pestova EV, Clayton AC, Zhang J, Roberts LR, Gores GJ, Halling KC, Kipp BR. An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples. Gastroenterology. 2015 Dec; 149 (7):1813-1824.e1 Epub 2015 Aug 29
    View PubMed
  179. Bhat M, Hathcock M, Kremers WK, Darwish Murad S, Schmit G, Martenson J, Alberts S, Rosen CB, Gores GJ, Heimbach J. Portal vein encasement predicts neoadjuvant therapy response in liver transplantation for perihilar cholangiocarcinoma protocol. Transpl Int. 2015 Dec; 28: (12)1383-91.
    View PubMed
  180. Gores GJ. Liver transplantation for cholangiocarcinoma. Liver Transpl. 2015 Nov; 21 Suppl 1:S32-3.
    View PubMed
  181. Ilyas SI, Eaton JE, Gores GJ. Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. Clin Gastroenterol Hepatol. 2015 Nov; 13 (12):2152-65 Epub 2015 June 05
    View PubMed
  182. Mukewar S, Gupta A, Baron TH, Gores G, Furutani K, Haddock MG, Hallemeier CL. Endoscopically inserted nasobiliary catheters for high dose-rate brachytherapy as part of neoadjuvant therapy for perihilar cholangiocarcinoma. Endoscopy. 2015 Oct; 47 (10):878-83 Epub 2015 May 11
    View PubMed
  183. Camilleri M, Gores GJ. Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol. 2015 Aug 15; 309 (4):G209-15 Epub 2015 July 02
    View PubMed
  184. Bamidele AO, Kremer KN, Hirsova P, Clift IC, Gores GJ, Billadeau DD, Hedin KE. IQGAP1 promotes CXCR4 chemokine receptor function and trafficking via EEA-1+ endosomes. J Cell Biol. 2015 Jul 20; 210 (2):257-72
    View PubMed
  185. Borad MJ, Gores GJ, Roberts LR. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. Curr Opin Gastroenterol. 2015 May; 31 (3):264-8
    View PubMed
  186. Yamada D, Rizvi S, Razumilava N, Bronk SF, Davila JI, Champion MD, Borad MJ, Bezerra JA, Chen X, Gores GJ. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology. 2015 May; 61 (5):1627-42 Epub 2015 Mar 20
    View PubMed
  187. Idrissova L, Malhi H, Werneburg NW, LeBrasseur NK, Bronk SF, Fingas C, Tchkonia T, Pirtskhalava T, White TA, Stout MB, Hirsova P, Krishnan A, Liedtke C, Trautwein C, Finnberg N, El-Deiry WS, Kirkland JL, Gores GJ. TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess. J Hepatol. 2015 May; 62 (5):1156-63 Epub 2014 Nov 28
    View PubMed
  188. Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol. 2015 Apr; 62 (1 Suppl):S144-56
    View PubMed
  189. Nanda A, Brown JM, Berger SH, Lewis MM, Barr Fritcher EG, Gores GJ, Keilin SA, Woods KE, Cai Q, Willingham FF. Triple modality testing by endoscopic retrograde cholangiopancreatography for the diagnosis of cholangiocarcinoma. Therap Adv Gastroenterol. 2015 Mar; 8 (2):56-65
    View PubMed
  190. Terzi E, Ray Kim W, Sanchez W, Charlton MR, Schmeltzer P, Gores GJ, Andrews JC, Smyrk TC, Heimbach JK. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl. 2015 Feb; 21 (2):248-57
    View PubMed
  191. Eaton JE, Barr Fritcher EG, Gores GJ, Atkinson EJ, Tabibian JH, Topazian MD, Gossard AA, Halling KC, Kipp BR, Lazaridis KN. Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2015 Feb; 110 (2):299-309 Epub 2015 Jan 27
    View PubMed
  192. Xiao F, Waldrop SL, Bronk SF, Gores GJ, Davis LS, Kilic G. Lipoapoptosis induced by saturated free fatty acids stimulates monocyte migration: a novel role for Pannexin1 in liver cells. Purinergic Signalling. 2015; 11(3):347-59.
    View PubMed
  193. Hirsova P, Gores GJ. Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis. Cell Mol Gastroenterol Hepatol. 2015 Jan; 1 (1):17-27
    View PubMed
  194. Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ, Gores GJ. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015; 35(3):953-66.
    View PubMed
  195. Rizvi S, Gores GJ. Molecular Profiling and Research of Therapeutic Targets. Dig Dis. 2015; 33 (4):586-9 Epub 2015 July 06
    View PubMed
  196. Yu T, Wang L, Lee H, O'Brien DK, Bronk SF, Gores GJ, Yoon Y. Decreasing mitochondrial fission prevents cholestatic liver injury. J Biol Chem. 2014 Dec 5; 289 (49):34074-88 Epub 2014 Oct 23
    View PubMed
  197. Chaiteerakij R, Harmsen WS, Marrero CR, Aboelsoud MM, Ndzengue A, Kaiya J, Therneau TM, Sanchez W, Gores GJ, Roberts LR. A new clinically based staging system for perihilar cholangiocarcinoma. Am J Gastroenterol. 2014 Dec; 109 (12):1881-90 Epub 2014 Nov 11
    View PubMed
  198. Bhat M, Chaiteerakij R, Harmsen WS, Schleck CD, Yang JD, Giama NH, Therneau TM, Gores GJ, Roberts LR. Metformin does not improve survival in patients with hepatocellular carcinoma. World J Gastroenterol. 2014 Nov 14; 20 (42):15750-5
    View PubMed
  199. Gores GJ. Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib. Nat Rev Gastroenterol Hepatol. 2014 Nov; 11 (11):645-7 Epub 2014 Sept 23
    View PubMed
  200. Gores GJ. Addressing unmet clinical needs: FISHing for bile duct cancer. Cancer Cytopathol. 2014 Nov; 122(11):789-90. Epub 2014 Oct 01.
    View PubMed
  201. Rizvi S, I Ilyas S, Borad MJ, Patel T, Gores GJ. Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis. 2014 Nov; 34 (4):456-64 Epub 2014 Nov 04
    View PubMed
  202. Ilyas SI, Mertens JC, Bronk SF, Hirsova P, Dai H, Roberts LR, Kaufmann SH, Gores GJ. Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. J Biol Chem. 2014 Aug 15; 289 (33):22835-22849 Epub 2014 June 27
    View PubMed
  203. Graham RP, Barr Fritcher EG, Pestova E, Schulz J, Sitailo LA, Vasmatzis G, Murphy SJ, McWilliams RR, Hart SN, Halling KC, Roberts LR, Gores GJ, Couch FJ, Zhang L, Borad MJ, Kipp BR. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014 Aug; 45(8):1630-8. Epub 2014 Apr 13.
    View PubMed
  204. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014 Jun 21; 383 (9935):2168-79 Epub 2014 Feb 26
    View PubMed
  205. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014 Jun; 60 (6):1268-89 Epub 2014 Mar 27
    View PubMed
  206. Singal AK, Kamath PS, Gores GJ, Shah VH. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol. 2014 Apr; 12 (4):555-64; quiz e31-2 Epub 2013 June 28
    View PubMed
  207. Razumilava N, Gradilone SA, Smoot RL, Mertens JC, Bronk SF, Sirica AE, Gores GJ. Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. J Hepatol. 2014 Mar; 60 (3):599-605 Epub 2013 Nov 14
    View PubMed
  208. Ibrahim SH, Gores GJ, Hirsova P, Kirby M, Miles L, Jaeschke A, Kohli R. Mixed lineage kinase 3 deficient mice are protected against the high fat high carbohydrate diet-induced steatohepatitis. Liver Int. 2014 Mar; 34 (3):427-37 Epub 2013 Nov 20
    View PubMed
  209. Sirica AE, Gores GJ. Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting. Hepatology. 2014; 59(6):2397-402.
    View PubMed
  210. Li J, Razumilava N, Gores GJ, Walters S, Mizuochi T, Mourya R, Bessho K, Wang YH, Glaser SS, Shivakumar P, Bezerra JA. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest. 2014; 124(7):3241-51.
    View PubMed
  211. Rizvi S, Gores GJ. Molecular pathogenesis of cholangiocarcinoma. Dig Dis. 2014; 32 (5):564-9 Epub 2014 July 14
    View PubMed
  212. Rizvi S, Gores GJ. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion. 2014; 89 (3):216-24 Epub 2014 May 22
    View PubMed
  213. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut. 2014; 63(5):844-55.
    View PubMed
  214. Guicciardi ME, Werneburg NW, Bronk SF, Franke A, Yagita H, Thomas G, Gores GJ. Cellular inhibitor of apoptosis (cIAP)-mediated ubiquitination of phosphofurin acidic cluster sorting protein 2 (PACS-2) negatively regulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity. PLoS One. 2014; 9 (3):e92124 Epub 2014 Mar 14
    View PubMed
  215. Terzic A, Harper CM Jr, Gores GJ, Pfenning MA. Regenerative medicine blueprint. Stem Cells Dev. 2013 Dec; 22 Suppl 1:20-4.
    View PubMed
  216. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJA, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, Tortora G, de Braud F, Scarpa A, Jarnagin W, Klimstra D, Karchin R, Velculescu VE, Hruban RH, Vogelstein B, Kinzler KW, Papadopoulos N, Wood LD. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013 Dec; 45 (12):1470-1473 Epub 2013 Nov 03
    View PubMed
  217. Barr Fritcher EG, Voss JS, Jenkins SM, Lingineni RK, Clayton AC, Roberts LR, Halling KC, Talwalkar JA, Gores GJ, Kipp BR. Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. Cancer Cytopathol. 2013 Dec; 121(12):708-17. Epub 2013 Jul 09.
    View PubMed
  218. Ilyas SI, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013 Dec; 145 (6):1215-29 Epub 2013 Oct 15
    View PubMed
  219. Akazawa Y, Guicciardi ME, Cazanave SC, Bronk SF, Werneburg NW, Kakisaka K, Nakao K, Gores GJ. Degradation of cIAPs contributes to hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol. 2013 Nov; 305 (9):G611-9 Epub 2013 Sept 05
    View PubMed
  220. Fingas CD, Mertens JC, Razumilava N, Sydor S, Bronk SF, Christensen JD, Rizvi SH, Canbay A, Treckmann JW, Paul A, Sirica AE, Gores GJ. Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Hepatology. 2013 Oct; 58(4):1362-74. Epub 2013 Aug 06.
    View PubMed
  221. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013 Sep; 145 (3):521-36 Epub 2013 July 01
    View PubMed
  222. Bhat M, Sonenberg N, Gores GJ. The mTOR pathway in hepatic malignancies. Hepatology. 2013 Aug; 58(2):810-8. Epub 2013 Apr 17.
    View PubMed
  223. Voss JS, Holtegaard LM, Kerr SE, Fritcher EG, Roberts LR, Gores GJ, Zhang J, Highsmith WE, Halling KC, Kipp BR. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol. 2013 Jul; 44 (7):1216-22 Epub 2013 Feb 04
    View PubMed
  224. Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, Gansen DN, de Groen PC, Lazaridis KN, Narayanan Menon KV, Larusso NF, Alberts SR, Gores GJ, Fleming CJ, Slettedahl SW, Harmsen WS, Therneau TM, Wiseman GA, Andrews JC, Roberts LR. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013 Jun; 36 (3):714-23 Epub 2012 Oct 24
    View PubMed
  225. Darwish Murad S, Heimbach JK, Gores GJ, Rosen CB, Benson JT, Kim WR. Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation. Liver Transpl. 2013 May; 19 (5):521-8 Epub 2013 Apr 09
    View PubMed
  226. Guicciardi ME, Malhi H, Mott JL, Gores GJ. Apoptosis and necrosis in the liver. Compr Physiol. 2013 Apr; 3 (2):977-1010
    View PubMed
  227. Chaiteerakij R, Yang JD, Harmsen WS, Slettedahl SW, Mettler TA, Fredericksen ZS, Kim WR, Gores GJ, Roberts RO, Olson JE, Therneau TM, Roberts LR. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology. 2013 Feb; 57 (2):648-55 Epub 2012 Dec 12
    View PubMed
  228. Mertens JC, Fingas CD, Christensen JD, Smoot RL, Bronk SF, Werneburg NW, Gustafson MP, Dietz AB, Roberts LR, Sirica AE, Gores GJ. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 2013 Jan 15; 73 (2):897-907 Epub 2012 Dec 05
    View PubMed
  229. Hirsova P, Ibrahim SH, Bronk SF, Yagita H, Gores GJ. Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis. PLoS One. 2013; 8 (7):e70599 Epub 2013 July 22
    View PubMed
  230. Gores GJ, Darwish Murad S, Heimbach JK, Rosen CB. Liver transplantation for perihilar cholangiocarcinoma. Dig Dis. 2013; 31(1):126-9. Epub 2013 Jun 17.
    View PubMed
  231. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013 Jan; 11 (1):13-21.e1; quiz e3-4 Epub 2012 Sept 13
    View PubMed
  232. Mathison A, Grzenda A, Lomberk G, Velez G, Buttar N, Tietz P, Hendrickson H, Liebl A, Xiong YY, Gores G, Fernandez-Zapico M, Larusso NF, Faubion W, Shah VH, Urrutia R. Role for Kruppel-like transcription factor 11 in mesenchymal cell function and fibrosis. PLoS One. 2013; 8 (9):e75311 Epub 2013 Sept 17
    View PubMed
  233. Krishnan A, Li X, Kao WY, Viker K, Butters K, Masuoka H, Knudsen B, Gores G, Charlton M. Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis. Lab Invest. 2012 Dec; 92 (12):1712-25 Epub 2012 Sept 24
    View PubMed
  234. Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, Highsmith WE, Zhang J, Roberts LR, Gores GJ, Halling KC. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012 Oct; 43 (10):1552-8 Epub 2012 Apr 12
    View PubMed
  235. Kakisaka K, Cazanave SC, Werneburg NW, Razumilava N, Mertens JC, Bronk SF, Gores GJ. A hedgehog survival pathway in 'undead' lipotoxic hepatocytes. J Hepatol. 2012 Oct; 57 (4):844-51 Epub 2012 May 26
    View PubMed
  236. Darwish Murad S, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, Alberts SR, Heimbach JK. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology. 2012 Sep; 56 (3):972-81 Epub 2012 July 17
    View PubMed
  237. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, Gores GJ, Dombrowski F, Evert M, Chen X, Willenbring H. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012 Aug 1; 122(8):2911-5. Epub 2012 Jul 17.
    View PubMed
  238. Yang JD, Kim B, Sanderson SO, Sauver JS, Yawn BP, Larson JJ, Therneau TM, Roberts LR, Gores GJ, Kim WR. Biliary tract cancers in Olmsted County, Minnesota, 1976-2008. Am J Gastroenterol. 2012 Aug; 107 (8):1256-62 Epub 2012 July 03
    View PubMed
  239. Yang JD, Kim WR, Park KW, Chaiteerakij R, Kim B, Sanderson SO, Larson JJ, Pedersen RA, Therneau TM, Gores GJ, Roberts LR, Park JW. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology. 2012 Aug; 56 (2):614-21 Epub 2012 July 02
    View PubMed
  240. Werneburg NW, Bronk SF, Guicciardi ME, Thomas L, Dikeakos JD, Thomas G, Gores GJ. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein-induced lysosomal translocation of proapoptotic effectors is mediated by phosphofurin acidic cluster sorting protein-2 (PACS-2). J Biol Chem. 2012 Jul 13; 287 (29):24427-37 Epub 2012 May 29
    View PubMed
  241. Rosen CB, Darwish Murad, Heimbach JK, Nyberg SL, Nagorney DM, Gores GJ. Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary? J Am Coll Surg. 2012 Jul; 215(1):31-8; discussion 38-40. Epub 2012 May 22.
    View PubMed
  242. Sembera S, Lammert C, Talwalkar JA, Sanderson SO, Poterucha JJ, Hay JE, Wiesner RH, Gores GJ, Rosen CB, Heimbach JK, Charlton MR. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl. 2012 Jul; 18 (7):803-10
    View PubMed
  243. Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, Hong JC, Emond JC, Jeon H, Rosen CB, Gores GJ, Heimbach JK. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012 Jul; 143 (1):88-98.e3; quiz e14 Epub 2012 Apr 12
    View PubMed
  244. Levy MJ, Heimbach JK, Gores GJ. Endoscopic ultrasound staging of cholangiocarcinoma. Curr Opin Gastroenterol. 2012 May; 28 (3):244-52
    View PubMed
  245. Levy MJ, Oberg TN, Campion MB, Clayton AC, Halling KC, Henry MR, Kipp BR, Sebo TJ, Zhang J, Enders FT, Clain JE, Gleeson FC, Rajan E, Roberts LR, Topazian MD, Wang KK, Gores GJ. Comparison of methods to detect neoplasia in patients undergoing endoscopic ultrasound-guided fine-needle aspiration. Gastroenterology. 2012 May; 142(5):1112-1121.e2. Epub 2012 Feb 07.
    View PubMed
  246. Fingas CD, Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ. Targeting PDGFR-beta in Cholangiocarcinoma. Liver Int. 2012 Mar; 32 (3):400-9 Epub 2011 Dec 02
    View PubMed
  247. Schneekloth TD, Jowsey SG, Biernacka JM, Burton MC, Vasquez AR, Bergquist T, Drews MS, Gores GJ. Pretransplant psychiatric and substance use comorbidity in patients with cholangiocarcinoma who received a liver transplant. Psychosomatics. 2012 Mar-Apr; 53(2):116-22.
    View PubMed
  248. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, OLT for. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012 Jan; 13(1):e11-22. Epub 2011 Oct 31.
    View PubMed
  249. An F, Yamanaka S, Allen S, Roberts LR, Gores GJ, Pawlik TM, Xie Q, Ishida M, Mezey E, Ferguson-Smith AC, Mori Y, Selaru FM. Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch. PLoS One. 2012; 7(10):e45606. Epub 2012 Oct 22.
    View PubMed
  250. Gores G, Lindor KD, Razumilava N. Gall bladder polyps in primary sclerosing cholangitis: Adhere to the guidelines. Hepatology. 2012; 56(1):396.
    View PubMed
  251. Kakisaka K, Cazanave SC, Fingas CD, Guicciardi ME, Bronk SF, Werneburg NW, Mott JL, Gores GJ. Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol. 2012 Jan 1; 302 (1):G77-84 Epub 2011 Oct 13
    View PubMed
  252. Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC, Mertens JC, Sirica AE, Gores GJ. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011 Dec; 54 (6):2076-88
    View PubMed
  253. Olaru AV, Ghiaur G, Yamanaka S, Luvsanjav D, An F, Popescu I, Alexandrescu S, Allen S, Pawlik TM, Torbenson M, Georgiades C, Roberts LR, Gores GJ, Ferguson-Smith A, Almeida MI, Calin GA, Mezey E, Selaru FM. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology. 2011 Dec; 54(6):2089-98.
    View PubMed
  254. Cazanave SC, Mott JL, Bronk SF, Werneburg NW, Fingas CD, Meng XW, Finnberg N, El-Deiry WS, Kaufmann SH, Gores GJ. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem. 2011 Nov 11; 286 (45):39336-48 Epub 2011 Sept 22
    View PubMed
  255. Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, Masuoko H, Gores G. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2011 Nov; 301 (5):G825-34 Epub 2011 Aug 11
    View PubMed
  256. Todisco A, Souza RF, Gores GJ. Trains, tracks, and promotion in an academic medical center. Gastroenterology. 2011 Nov; 141(5):1545-8. Epub 2011 Sep 19.
    View PubMed
  257. Barr Fritcher EG, Kipp BR, Voss JS, Clayton AC, Lindor KD, Halling KC, Gores GJ. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol. 2011 Nov; 106(11):2023-8. Epub 2011 Aug 16.
    View PubMed
  258. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011 Nov; 54 (5):1842-52
    View PubMed
  259. Meng XW, Peterson KL, Dai H, Schneider P, Lee SH, Zhang JS, Koenig A, Bronk S, Billadeau DD, Gores GJ, Kaufmann SH. High cell surface death receptor expression determines type I versus type II signaling. J Biol Chem. 2011 Oct 14; 286 (41):35823-35833 Epub 2011 Aug 24
    View PubMed
  260. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011 Aug 2; 8 (9):512-22 Epub 2011 Aug 02
    View PubMed
  261. Cazanave SC, Mott JL, Elmi NA, Bronk SF, Masuoka HC, Charlton MR, Gores GJ. A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res. 2011 Aug; 52 (8):1517-25 Epub 2011 June 01
    View PubMed
  262. Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr. 2011 Aug; 53 (2):131-40
    View PubMed
  263. Kang N, Gores GJ, Shah VH. Hepatic stellate cells: partners in crime for liver metastases? Hepatology. 2011 Aug; 54 (2):707-13
    View PubMed
  264. Rong G, Zhong R, Lleo A, Leung PS, Bowlus CL, Yang GX, Yang CY, Coppel RL, Ansari AA, Cuebas DA, Worman HJ, Invernizzi P, Gores GJ, Norman G, He XS, Gershwin ME. Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology. 2011 Jul; 54(1):196-203.
    View PubMed
  265. Wong BS, Camilleri M, Carlson PJ, Guicciardi ME, Burton D, McKinzie S, Rao AS, Zinsmeister AR, Gores GJ. A Klothobeta variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology. 2011 Jun; 140 (7):1934-42 Epub 2011 Mar 09
    View PubMed
  266. Breuhahn K, Gores G, Schirmacher P. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology. 2011 Jun; 53(6):2112-21.
    View PubMed
  267. Heimbach JK, Sanchez W, Rosen CB, Gores GJ. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford). 2011 May; 13 (5):356-60 Epub 2011 Mar 29
    View PubMed
  268. Deoliveira ML, Schulick RD, Nimura Y, Rosen C, Gores G, Neuhaus P, Clavien PA. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology. 2011 Apr; 53(4):1363-71.
    View PubMed
  269. Ibrahim SH, Akazawa Y, Cazanave SC, Bronk SF, Elmi NA, Werneburg NW, Billadeau DD, Gores GJ. Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis. J Hepatol. 2011 Apr; 54(4):765-72. Epub 2010 Nov 23.
    View PubMed
  270. Kurita S, Mott JL, Cazanave SC, Fingas CD, Guicciardi ME, Bronk SF, Roberts LR, Fernandez-Zapico ME, Gores GJ. Hedgehog inhibition promotes a switch from Type II to Type I cell death receptor signaling in cancer cells. PLoS One. 2011 Mar 31; 6 (3):e18330
    View PubMed
  271. Gores GJ. Practical management of hepatocellular carcinoma. Gut and Liver. 2011; 135-8.
  272. Guicciardi ME, Mott JL, Bronk SF, Kurita S, Fingas CD, Gores GJ. Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Exp Cell Res. 2011 Jan 1; 317 (1):107-16 Epub 2010 Oct 14
    View PubMed
  273. Wong BS, Camilleri M, Carlson PJ, Guicciardi ME, Burton D, McKinzie S, Rao AS, Zinsmeister AR, Gores GJ. A klotho beta variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology. 2011; 140(7):1934-42.
  274. Blechacz B, Gores GJ. Positron emission tomography scan for a hepatic mass. Hepatology. 2010 Dec; 52 (6):2186-91
    View PubMed
  275. Guicciardi ME, Gores GJ. Apoptosis as a mechanism for liver disease progression. Semin Liver Dis. 2010 Nov; 30 (4):402-10 Epub 2010 Oct 19
    View PubMed
  276. Kipp BR, Fritcher EG, Clayton AC, Gores GJ, Roberts LR, Zhang J, Levy MJ, Halling KC. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn. 2010 Nov; 12(6):780-6. Epub 2010 Sep 23.
    View PubMed
  277. Lleo A, Bowlus CL, Yang GX, Invernizzi P, Podda M, Van de Water J, Ansari AA, Coppel RL, Worman HJ, Gores GJ, Gershwin ME. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology. 2010 Sep; 52(3):987-98.
    View PubMed
  278. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010 Sep 1; 28(25):3994-4005. Epub 2010 Aug 02.
    View PubMed
  279. Kurita S, Mott JL, Almada LL, Bronk SF, Werneburg NW, Sun SY, Roberts LR, Fernandez-Zapico ME, Gores GJ. GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis. Oncogene. 2010 Aug 26; 29 (34):4848-58 Epub 2010 June 21
    View PubMed
  280. Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott J, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology. 2010 Aug; 52 (2):550-61
    View PubMed
  281. Sosa Seda IM, Mott JL, Akazawa Y, Barreyro FJ, Bronk SF, Kaufmann SH, Gores GJ. Noxa mediates hepatic stellate cell apoptosis by proteasome inhibition. Hepatol Res. 2010 Jul 1; 40 (7):701-10 Epub 2010 June 14
    View PubMed
  282. Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol Rev. 2010 Jul; 90 (3):1165-94
    View PubMed
  283. Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int. 2010 Jul; 23 (7):692-7 Epub 2010 May 20
    View PubMed
  284. Cazanave SC, Elmi NA, Akazawa Y, Bronk SF, Mott JL, Gores GJ. CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol. 2010 Jul; 299 (1):G236-43 Epub 2010 Apr 29
    View PubMed
  285. Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology. 2010 Jul; 52 (1):349-59
    View PubMed
  286. Kurita S, Higuchi H, Saito Y, Nakamoto N, Takaishi H, Tada S, Saito H, Gores GJ, Hibi T. DNMT1 and DNMT3b silencing sensitizes human hepatoma cells to TRAIL-mediated apoptosis via up-regulation of TRAIL-R2/DR5 and caspase-8. Cancer Sci. 2010 Jun; 101 (6):1431-9 Epub 2010 Mar 13
    View PubMed
  287. Akazawa Y, Cazanave S, Mott JL, Elmi N, Bronk SF, Kohno S, Charlton MR, Gores GJ. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol. 2010 Apr; 52 (4):586-93 Epub 2010 Feb 13
    View PubMed
  288. Smoot RL, Blechacz BR, Werneburg NW, Bronk SF, Sinicrope FA, Sirica AE, Gores GJ. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res. 2010 Mar 1; 70 (5):1960-9 Epub 2010 Feb 16
    View PubMed
  289. Escande C, Chini CC, Nin V, Dykhouse KM, Novak CM, Levine J, van Deursen J, Gores GJ, Chen J, Lou Z, Chini EN. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest. 2010 Feb; 120 (2):545-58 Epub 2010 Jan 11
    View PubMed
  290. Cazanave SC, Gores GJ. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol. 2010 Feb 1; 5 (1):71-85
    View PubMed
  291. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ, American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010 Feb; 51(2):660-78.
    View PubMed
  292. Yu L, Feng M, Kim H, Phung Y, Kleiner DE, Gores GJ, Qian M, Wang XW, Ho M. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer. 2010; 1:141-9. Epub 2010 Oct 1
    View PubMed
  293. Bangarulingam SY, Bjornsson E, Enders F, Barr Fritcher EG, Gores G, Halling KC, Lindor KD. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology. 2010 Jan; 51 (1):174-80
    View PubMed
  294. Rockey D, Gores GJ. Current Opinion in Gastroenterology: Editorial introductions. Curr Opin Gastroenterol. 2010; 26(3).
  295. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009 Dec; 137 (6):2010-7 Epub 2009 Sept 18
    View PubMed
  296. Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology. 2009 Dec; 50 (6):1861-70
    View PubMed
  297. Multisociety Task Force, Friedman LS, Brandt LJ, Elta GH, Fitz JG, Gores GJ, Katz PO, Kuemmerle JF, Pardi DS, Vargo JJ, Stolar MH. Report of the Multisociety Task Force on GI training. Hepatology. 2009 Nov; 50(5):1325-9.
    View PubMed
  298. Multisociety Task Force, Friedman LS, Brandt LJ, Elta GH, Fitz JG, Gores GJ, Katz PO, Kuemmerle JF, Pardi DS, Vargo JJ, Stolar MH. Report of the Multisociety Task Force on GI training. Gastrointest Endosc. 2009 Nov; 70(5):823-7.
    View PubMed
  299. Friedman LS, Brandt LJ, Elta GH, Fitz JG, Gores GJ, Katz PO, Kuemmerle JF, Pardi DS, Vargo JJ, Stolar MH. Report of the multisociety task force on GI training. Gastroenterology. 2009 Nov; 137(5):1839-43.
    View PubMed
  300. Masuoka HC, Mott J, Bronk SF, Werneburg NW, Akazawa Y, Kaufmann SH, Gores GJ. Mcl-1 degradation during hepatocyte lipoapoptosis. J Biol Chem. 2009 Oct 30; 284 (44):30039-48 Epub 2009 Sept 05
    View PubMed
  301. Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, Kahraman A, Garrison SP, Zambetti GP, Charlton MR, Gores GJ. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem. 2009 Sep 25; 284 (39):26591-602 Epub 2009 July 28
    View PubMed
  302. Kahraman A, Mott JL, Bronk SF, Werneburg NW, Barreyro FJ, Guicciardi ME, Akazawa Y, Braley K, Craig RW, Gores GJ. Overexpression of mcl-1 attenuates liver injury and fibrosis in the bile duct-ligated mouse. Dig Dis Sci. 2009 Sep; 54 (9):1908-17 Epub 2008 Dec 03
    View PubMed
  303. Beraza N, Malato Y, Sander LE, Al-Masaoudi M, Freimuth J, Riethmacher D, Gores GJ, Roskams T, Liedtke C, Trautwein C. Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage. J Exp Med. 2009 Aug 3; 206(8):1727-37. Epub 2009 Jul 27.
    View PubMed
  304. Masuoka HC, Guicciardi ME, Gores GJ. Caspase inhibitors for the treatment of hepatitis C. Clin Liver Dis. 2009 Aug; 13 (3):467-75
    View PubMed
  305. Kahraman A, Bronk SF, Cazanave S, Werneburg NW, Mott JL, Contreras PC, Gores GJ. Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse. Hepatol Res. 2009 Aug; 39 (8):805-13 Epub 2009 July 13
    View PubMed
  306. Gores GJ. Hepatology: a home for hepatocellular cancer publications. Hepatology. 2009 Jul; 50 (1):1-2
    View PubMed
  307. Fritcher EG, Kipp BR, Halling KC, Oberg TN, Bryant SC, Tarrell RF, Gores GJ, Levy MJ, Clayton AC, Sebo TJ, Roberts LR. A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology. 2009 Jun; 136(7):2180-6. Epub 2009 Feb 14.
    View PubMed
  308. Akazawa Y, Mott JL, Bronk SF, Werneburg NW, Kahraman A, Guicciardi ME, Meng XW, Kohno S, Shah VH, Kaufmann SH, McNiven MA, Gores GJ. Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. Gastroenterology. 2009 Jun; 136 (7):2365-2376.e1-7 Epub 2009 Mar 09
    View PubMed
  309. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J. 2009 Jun; 23 (6):1625-37 Epub 2009 Jan 13
    View PubMed
  310. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009 May 5; 100 (9):1385-92
    View PubMed
  311. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, Hamilton JP, Abraham J, Georgiades C, Alvarez H, Vivekanandan P, Yu W, Maitra A, Torbenson M, Thuluvath PJ, Gores GJ, LaRusso NF, Hruban R, Meltzer SJ. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009 May; 49(5):1595-601.
    View PubMed
  312. Rea DJ, Rosen CB, Nagorney DM, Heimbach JK, Gores GJ. Transplantation for cholangiocarcinoma: when and for whom? Surg Oncol Clin N Am. 2009 Apr; 18 (2):325-37, ix
    View PubMed
  313. O'Hara SP, Mott JL, Splinter PL, Gores GJ, LaRusso NF. MicroRNAs: key modulators of posttranscriptional gene expression. Gastroenterology. 2009 Jan; 136 (1):17-25 Epub 2008 Dec 03
    View PubMed
  314. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant. 2009 Jan; 9 (1):201-9 Epub 2008 Oct 31
    View PubMed
  315. Sirica AE, Nathanson MH, Gores GJ, Larusso NF. Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference. Hepatology. 2008 Dec; 48(6):2040-6.
    View PubMed
  316. Gleeson FC, Clayton AC, Zhang L, Clain JE, Gores GJ, Rajan E, Smyrk TC, Topazian MD, Wang KK, Wiersema MJ, Levy MJ. Adequacy of endoscopic ultrasound core needle biopsy specimen of nonmalignant hepatic parenchymal disease. Clin Gastroenterol Hepatol. 2008 Dec; 6(12):1437-40. Epub 2008 Jul 26.
    View PubMed
  317. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008 Dec; 135 (6):1953-60 Epub 2008 Sept 13
    View PubMed
  318. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis. 2008 Nov; 28 (4):360-9 Epub 2008 Oct 27
    View PubMed
  319. Decker NK, Abdelmoneim SS, Yaqoob U, Hendrickson H, Hormes J, Bentley M, Pitot H, Urrutia R, Gores GJ, Shah VH. Nitric oxide regulates tumor cell cross-talk with stromal cells in the tumor microenvironment of the liver. Am J Pathol. 2008 Oct; 173 (4):1002-12 Epub 2008 Aug 28
    View PubMed
  320. Rustgi VK, Davis GL, Herrine SK, McCullough AJ, Friedman SL, Gores GJ. Future trends in hepatology: challenges and opportunities. Hepatology. 2008 Aug; 48(2):655-61.
    View PubMed
  321. Mott JL, Bronk SF, Mesa RA, Kaufmann SH, Gores GJ. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther. 2008 Aug; 7 (8):2339-47
    View PubMed
  322. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008 Jul; 48 (1):308-21
    View PubMed
  323. Gores GJ. Apoptosis and hepatic necroinflammation. Gastroenterol Hepatol (N Y). 2008 Jun; 4 (6):394-5
    View PubMed
  324. Langer DA, Das A, Semela D, Kang-Decker N, Hendrickson H, Bronk SF, Katusic ZS, Gores GJ, Shah VH. Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology. 2008 Jun; 47 (6):1983-93
    View PubMed
  325. Llovet JM, Di Bisceglie, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, Panel of. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008 May 21; 100(10):698-711. Epub 2008 May 13
    View PubMed
  326. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology. 2008 May; 134 (6):1641-54
    View PubMed
  327. Levy MJ, Baron TH, Clayton AC, Enders FB, Gostout CJ, Halling KC, Kipp BR, Petersen BT, Roberts LR, Rumalla A, Sebo TJ, Topazian MD, Wiersema MJ, Gores GJ. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol. 2008 May; 103 (5):1263-73
    View PubMed
  328. Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology. 2008 May; 47(5):1495-503.
    View PubMed
  329. Kahraman A, Barreyro FJ, Bronk SF, Werneburg NW, Mott JL, Akazawa Y, Masuoka HC, Howe CL, Gores GJ. TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology. 2008 Apr; 47 (4):1317-30
    View PubMed
  330. Gleeson FC, Rajan E, Levy MJ, Clain JE, Topazian MD, Harewood GC, Papachristou GI, Takahashi N, Rosen CB, Gores GJ. EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc. 2008 Mar; 67(3):438-43. Epub 2007 Dec 03.
    View PubMed
  331. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008 Feb; 12 (1):131-50, ix
    View PubMed
  332. Guicciardi ME, Gores GJ. Cell stress gives a red light to the mitochondrial cell death pathway. Sci Signal. 2008; 1: (7)pe9.
    View PubMed
  333. Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford). 2008; 10 (3):186-9
    View PubMed
  334. Baskin-Bey ES, Anan A, Isomoto H, Bronk SF, Gores GJ. Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse. World J Gastroenterol. 2007 Nov 14; 13 (42):5635-41
    View PubMed
  335. Akazawa Y, Gores GJ. Death receptor-mediated liver injury. Semin Liver Dis. 2007 Nov; 27(4):327-38.
    View PubMed
  336. Mantel HT, Rosen CB, Heimbach JK, Nyberg SL, Ishitani MB, Andrews JC, McKusick MA, Haddock MG, Alberts SR, Gores GJ. Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl. 2007 Oct; 13(10):1372-81.
    View PubMed
  337. Gores GJ, Nagorney DM, Rosen CB. Cholangiocarcinoma: is transplantation an option? For whom? J Hepatol. 2007 Oct; 47(4):455-9. Epub 2007 Jul 25.
    View PubMed
  338. Werneburg NW, Guicciardi ME, Bronk SF, Kaufmann SH, Gores GJ. Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. J Biol Chem. 2007 Sep 28; 282 (39):28960-28970 Epub 2007 Aug 08
    View PubMed
  339. Barreyro FJ, Kobayashi S, Bronk SF, Werneburg NW, Malhi H, Gores GJ. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem. 2007 Sep 14; 282 (37):27141-27154 Epub 2007 July 11
    View PubMed
  340. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007 Sep 13; 26 (42):6133-40 Epub 2007 Apr 02
    View PubMed
  341. Mott JL, Gores GJ. Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death. Hepatology. 2007 Sep; 46(3):906-11.
    View PubMed
  342. Levy MJ, Clain JE, Clayton A, Halling KC, Kipp BR, Rajan E, Roberts LR, Root RM, Sebo TJ, Topazian MD, Wang KK, Wiersema MJ, Gores GJ. Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc. 2007 Sep; 66 (3):483-90
    View PubMed
  343. Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut. 2007 Aug; 56 (8):1124-31 Epub 2007 Apr 30
    View PubMed
  344. Barr Fritcher EG, Kipp BR, Slezak JM, Moreno-Luna LE, Gores GJ, Levy MJ, Roberts LR, Halling KC, Sebo TJ. Correlating routine cytology, quantitative nuclear morphometry by digital image analysis, and genetic alterations by fluorescence in situ hybridization to assess the sensitivity of cytology for detecting pancreatobiliary tract malignancy. Am J Clin Pathol. 2007 Aug; 128(2):272-9.
    View PubMed
  345. Kobayashi S, Lee SH, Meng XW, Mott JL, Bronk SF, Werneburg NW, Craig RW, Kaufmann SH, Gores GJ. Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem. 2007 Jun 22; 282 (25):18407-18417 Epub 2007 Apr 25
    View PubMed
  346. Rosen CB, Heimbach JK, Gores GJ. Current status of liver transplantation for hilar cholangiocarcinoma. Curr Opin Organ Transplant. 2007 Jun; 12 (3):215-219
    View PubMed
  347. Lazaridis KN, Gores GJ. Our new president--Nicholas F. LaRusso, MD. Gastroenterology. 2007 May; 132 (5):2005-11
    View PubMed
  348. Guicciardi ME, Bronk SF, Werneburg NW, Gores GJ. cFLIPL prevents TRAIL-induced apoptosis of hepatocellular carcinoma cells by inhibiting the lysosomal pathway of apoptosis. Am J Physiol Gastrointest Liver Physiol. 2007 May; 292 (5):G1337-46 Epub 2007 Feb 01
    View PubMed
  349. Alberts SR, Gores GJ, Kim GP, Roberts LR, Kendrick ML, Rosen CB, Chari ST, Martenson JA. Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc. 2007 May; 82 (5):628-37
    View PubMed
  350. Oxentenko AS, Pardi DS, Schmoll JA, Gores GJ. Factors predicting initial career choices in gastroenterology fellows. J Clin Gastroenterol. 2007 May-Jun; 41 (5):445-50
    View PubMed
  351. Leerapun A, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, Mettler TA, Stadheim LM, Aderca I, Moser CD, Nagorney DM, LaRusso NF, de Groen PC, Menon KV, Lazaridis KN, Gores GJ, Charlton MR, Roberts RO, Therneau TM, Katzmann JA, Roberts LR. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol. 2007 Mar; 5 (3):394-402; quiz 267
    View PubMed
  352. Ustundag Y, Bronk SF, Gores GJ. Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells. World J Gastroenterol. 2007 Feb 14; 13 (6):851-7
    View PubMed
  353. O'Hara SP, Small AJ, Nelson JB, Badley AD, Chen XM, Gores GJ, Larusso NF. The human immunodeficiency virus type 1 tat protein enhances Cryptosporidium parvum-induced apoptosis in cholangiocytes via a Fas ligand-dependent mechanism. Infect Immun. 2007 Feb; 75 (2):684-96 Epub 2006 Nov 21
    View PubMed
  354. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, Gores GJ. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology. 2007 Jan; 132 (1):384-96 Epub 2006 Nov 07
    View PubMed
  355. Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, Burgart L, Garrity-Park M, van Vilsteren FG, Oliver LK, Rosen CB, Gores GJ. Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury. Am J Transplant. 2007 Jan; 7 (1):218-25
    View PubMed
  356. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, Nyberg SL, Ishitani MB, Rosen CB. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation. 2006 Dec 27; 82(12):1703-7.
    View PubMed
  357. Gores GJ, Gish RG, Sudan D, Rosen CB, MELD Exception Study Group. Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. Liver Transpl. 2006 Dec; 12(12 Suppl 3):S95-7.
    View PubMed
  358. Allina J, Hu B, Sullivan DM, Fiel MI, Thung SN, Bronk SF, Huebert RC, van de Water J, LaRusso NF, Gershwin ME, Gores GJ, Odin JA. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun. 2006 Dec; 27(4):232-41. Epub 2007 Jan 10.
    View PubMed
  359. Gwak GY, Yoon JH, Lee SH, Lee SM, Lee HS, Gores GJ. Lysophosphatidylcholine suppresses apoptotic cell death by inducing cyclooxygenase-2 expression via a Raf-1 dependent mechanism in human cholangiocytes. J Cancer Res Clin Oncol. 2006 Dec; 132(12):771-9. Epub 2006 Jun 29.
    View PubMed
  360. Gores GJ, Gish RG, Shrestha R, Wiesner RH. Model for end-stage liver disease (MELD) exception for bacterial cholangitis. Liver Transpl. 2006 Dec; 12(12 Suppl 3):S91-2.
    View PubMed
  361. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol. 2006 Dec; 45 (6):856-67 Epub 2006 Sept 25
    View PubMed
  362. Malhi H, Gores GJ. TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene. 2006 Nov 30; 25: (56)7333-5.
    View PubMed
  363. Moreno Luna LE, Gores GJ. Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl. 2006 Nov; 12(11 Suppl 2):S15-9.
    View PubMed
  364. Moreno Luna LE, Kipp B, Halling KC, Sebo TJ, Kremers WK, Roberts LR, Barr Fritcher EG, Levy MJ, Gores GJ. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology. 2006 Oct; 131 (4):1064-72 Epub 2006 Aug 16
    View PubMed
  365. Anan A, Baskin-Bey ES, Isomoto H, Mott JL, Bronk SF, Albrecht JH, Gores GJ. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. Am J Physiol Gastrointest Liver Physiol. 2006 Oct; 291(4):G709-16. Epub 2006 Jun 22.
    View PubMed
  366. Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert Opin Emerg Drugs. 2006 Sep; 11 (3):469-87
    View PubMed
  367. Heimbach JK, Gores GJ, Nagorney DM, Rosen CB. Liver transplantation for perihilar cholangiocarcinoma after aggressive neoadjuvant therapy: a new paradigm for liver and biliary malignancies? Surgery. 2006 Sep; 140(3):331-4.
    View PubMed
  368. Bambha K, Nagorney D, Sanderson S, Gores GJ. Hepatic adenomatosis in a young woman with glucose intolerance. Nat Clin Pract Gastroenterol Hepatol. 2006 Sep; 3: (9)526-31; quiz (following 531).
    View PubMed
  369. LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, Hoofnagle JH. Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006 Sep; 44 (3):746-64
    View PubMed
  370. Simmons DT, Baron TH, Petersen BT, Gostout CJ, Haddock MG, Gores GJ, Yeakel PD, Topazian MD, Levy MJ. A novel endoscopic approach to brachytherapy in the management of Hilar cholangiocarcinoma. Am J Gastroenterol. 2006 Aug; 101: (8)1792-6.
    View PubMed
  371. Varela M, Sanchez W, Bruix J, Gores GJ. Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl. 2006 Jul; 12(7):1028-36.
    View PubMed
  372. Baskin-Bey ES, Huang W, Ishimura N, Isomoto H, Bronk SF, Braley K, Craig RW, Moore DD, Gores GJ. Constitutive androstane receptor (CAR) ligand, TCPOBOP, attenuates Fas-induced murine liver injury by altering Bcl-2 proteins. Hepatology. 2006 Jul; 44 (1):252-62
    View PubMed
  373. Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S, Stiles B, Wang RH, Ohara N, Yoshino T, LeRoith D, Torbenson MS, Gores GJ, Wu H, Gao B, Deng CX. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest. 2006 Jul; 116(7):1843-52. Epub 2006 Jun 08.
    View PubMed
  374. Feldstein AE, Werneburg NW, Li Z, Bronk SF, Gores GJ. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol. 2006 Jun; 290(6):G1339-46. Epub 2006 Feb 16.
    View PubMed
  375. Malhi H, Gores GJ. Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther. 2006 May 01; 23: (9)1287-96.
    View PubMed
  376. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem. 2006 Apr 28; 281 (17):12093-101 Epub 2006 Feb 27
    View PubMed
  377. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, Gores GJ, Hobday TJ. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. Liver Transpl. 2006 Mar; 12(3):448-56.
    View PubMed
  378. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis. 2006 Feb; 26 (1):42-51
    View PubMed
  379. Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology. 2006 Feb; 43 (2):335-44
    View PubMed
  380. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology. 2006 Feb; 43 (2 Suppl 1):S31-44
    View PubMed
  381. Kim WR, Therneau TM, Benson JT, Kremers WK, Rosen CB, Gores GJ, Dickson ER. Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology. 2006 Feb; 43 (2):345-51
    View PubMed
  382. Ishimura N, Isomoto H, Bronk SF, Gores GJ. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol. 2006 Jan; 290(1):G129-36. Epub 2005 Sep 15.
    View PubMed
  383. Sanchez W, Talwalkar JA, Gores GJ. "Will all liver transplantation patients eventually die from cancer?". J Hepatol. 2006 Jan; 44(1):13-8. Epub 2005 Nov 07.
    View PubMed
  384. Baskin-Bey ES, Gores GJ. Death by association: BH3 domain-only proteins and liver injury. Am J Physiol Gastrointest Liver Physiol. 2005 Dec; 289(6):G987-90.
    View PubMed
  385. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, Gores GJ. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005 Dec; 42: (6)1329-38.
    View PubMed
  386. Wuestefeld T, Klein C, Streetz KL, Beraza N, Scholmerich J, Burgart L, Zender L, Kubicka S, Gores GJ, Manns MP, Trautwein C. Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice. Hepatology. 2005 Nov; 42(5):1082-90.
    View PubMed
  387. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005 Oct 20; 24 (46):6861-9
    View PubMed
  388. Gawrieh S, Papouchado BG, Burgart LJ, Kobayashi S, Charlton MR, Gores GJ. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2005 Oct; 11(10):1207-13.
    View PubMed
  389. Minagawa N, Kruglov EA, Dranoff JA, Robert ME, Gores GJ, Nathanson MH. The anti-apoptotic protein Mcl-1 inhibits mitochondrial Ca2+ signals. J Biol Chem 2005 Sep 30; 280(39):33637-44.
    View PubMed
  390. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci. 2005 Sep 1; 10(Suppl S):3093-9.
    View PubMed
  391. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005 Sep; 242 (3):451-8; discussion 458-61
    View PubMed
  392. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005 Sep; 50(9):1734-40.
    View PubMed
  393. Kim WR, Gores GJ, Benson JT, Therneau TM, Melton LJ 3rd. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology. 2005 Aug; 129 (2):486-93
    View PubMed
  394. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005 Jul; 54 (7):1024-33
    View PubMed
  395. Guicciardi ME, Bronk SF, Werneburg NW, Yin XM, Gores GJ. Bid is upstream of lysosome-mediated caspase 2 activation in tumor necrosis factor alpha-induced hepatocyte apoptosis. Gastroenterology. 2005 Jul; 129 (1):269-84
    View PubMed
  396. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005 Jun; 128 (7):2054-65
    View PubMed
  397. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology. 2005 May; 128 (5):1354-68
    View PubMed
  398. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005 May; 128 (6):1655-67
    View PubMed
  399. Feldstein AE, Papouchado BG, Angulo P, Sanderson S, Angulo P, Sanderson S, Adams L, Gores GJ. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2005 Apr; 3 (4):384-9
    View PubMed
  400. Slijkhuis WA, Stadheim L, Hassoun ZM, Nzeako UC, Kremers WK, Talwalkar JA, Gores GJ. Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol. 2005 Apr; 39 (4):333-8
    View PubMed
  401. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol. 2005 Mar; 42(3):358-64.
    View PubMed
  402. Stewart CA, Reivich M, Lucey MR, Gores GJ. Neuroimaging in hepatic encephalopathy. Clin Gastroenterol Hepatol. 2005 Mar; 3 (3):197-207
    View PubMed
  403. Harewood GC, Baron TH, Rumalla A, Wang KK, Gores GJ, Stadheim LM, de Groen PC. Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. J Gastroenterol Hepatol. 2005 Mar; 20: (3)415-20.
    View PubMed
  404. Canbay A, Gieseler RK, Gores GJ, Gerken G. The relationship between apoptosis and non-alcoholic fatty liver disease: An evolutionary cornerstone turned pathogenic. Z Gastroenterol. 2005 Feb; 43(2):211-7.
    View PubMed
  405. Baskin-Bey ES, Canbay A, Bronk SF, Werneburg N, Guicciardi ME, Nyberg SL, Gores GJ. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. Am J Physiol Gastrointest Liver Physiol. 2005 Feb; 288(2):G396-G402.
    View PubMed
  406. Ghobrial IM, Habermann TM, Macon WR, Ristow KM, Larson TS, Walker RC, Ansell SM, Gores GJ, Stegall MD, McGregor CG. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation. 2005 Jan 27; 79 (2):244-7
    View PubMed
  407. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis. 2005; 25 (2):212-25
    View PubMed
  408. Baskin-Bey ES, Devarbhavi HC, Nagorney DM, Farnell MB, Donohue JH, Sanderson SO, Stadheim LM, Gores GJ. Idiopathic benign biliary strictures in surgically resected patients with presumed cholangiocarcinoma. HPB (Oxford). 2005; 7 (4):283-8
    View PubMed
  409. Ishimura N, Gores GJ. The death receptor TRAIL in cancer cell apoptosis. Ann. Cancer Res. Ther. 2005; 13(1-2):10.
  410. Chiorean MV, Guicciardi ME, Yoon JH, Bronk SF, Kaufmanns SH, Gores GJ. Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. Liver Int. 2004 Dec; 24 (6):687-95
    View PubMed
  411. Johnson ME, Uhl CB, Spittler KH, Wang H, Gores GJ. Mitochondrial injury and caspase activation by the local anesthetic lidocaine. Anesthesiology. 2004 Nov; 101 (5):1184-94
    View PubMed
  412. Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology. 2004 Nov; 127 (5 Suppl 1):S126-32
    View PubMed
  413. Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol. 2004 Nov; 41(5):808-14.
    View PubMed
  414. Gores GJ, Baskin-Bey ES, Baron TH, Alberts SR. Treatment endpoints for advanced cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2004 Nov; 1(1):4-5.
    View PubMed
  415. Heimbach JK, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB, Gores GJ. Transplantation for hilar cholangiocarcinoma. Liver Transpl. 2004 Oct; 10(10 Suppl 2):S65-8.
    View PubMed
  416. Kipp BR, Stadheim LM, Halling SA, Pochron NL, Harmsen S, Nagorney DM, Sebo TJ, Therneau TM, Gores GJ, de Groen PC, Baron TH, Levy MJ, Halling KC, Roberts LR. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol. 2004 Sep; 99(9):1675-81.
    View PubMed
  417. Werneburg N, Guicciardi ME, Yin XM, Gores GJ. TNF-alpha-mediated lysosomal permeabilization is FAN and caspase 8/Bid dependent. Am J Physiol Gastrointest Liver Physiol. 2004 Aug; 287(2):G436-43. Epub 2004 Apr 08.
    View PubMed
  418. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004 Jul; 40 (1):185-94
    View PubMed
  419. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol. 2004 Jul; 287 (1):G88-95 Epub 2004 Feb 19
    View PubMed
  420. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 2004 May 15; 64 (10):3517-24
    View PubMed
  421. Matsumura S, Van de Water J, Leung P, Odin JA, Yamamoto K, Gores GJ, Mostov K, Ansari AA, Coppel RL, Shiratori Y, Gershwin ME. Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis. Hepatology. 2004 May; 39(5):1415-22.
    View PubMed
  422. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004 May; 24(2):201-7.
    View PubMed
  423. Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. Oncogene. 2004 Apr 12; 23(16):2881-90.
    View PubMed
  424. Yoon JH, Canbay AE, Werneburg NW, Lee SP, Gores GJ. Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: Implications for biliary tract carcinogenesis. Hepatology. 2004 Mar; 39(3):732-8.
    View PubMed
  425. Shah V, Lyford G, Gores G, Gores G, Farrugia G. Nitric oxide in gastrointestinal health and disease. Gastroenterology. 2004 Mar; 126 (3):903-13
    View PubMed
  426. Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther. 2004 Mar; 308 (3):1191-6 Epub 2003 Nov 14
    View PubMed
  427. Strand S, Strand D, Seufert R, Mann A, Lotz J, Blessing M, Lahn M, Wunsch A, Broering DC, Hahn U, Grischke EM, Rogiers X, Otto G, Gores GJ, Galle PR. Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome. Gastroenterology. 2004 Mar; 126(3):849-58.
    View PubMed
  428. Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl. 2004 Mar; 10 (3):449-55
    View PubMed
  429. Baron TH, Harewood GC, Rumalla A, Pochron NL, Stadheim LM, Gores GJ, Therneau TM, De Groen PC, Sebo TJ, Salomao DR, Kipp BR. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol. 2004 Mar; 2 (3):214-9
    View PubMed
  430. Menon KV, Menon KV, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine CJ, Shah V. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol. 2004 Feb; 99 (2):255-60
    View PubMed
  431. Higuchi H, Grambihler A, Canbay A, Bronk SF, Gores GJ. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem. 2004 Jan 2; 279 (1):51-60 Epub 2003 Oct 14
    View PubMed
  432. Maeda T, Taguchi K, Aishima S, Shimada M, Hintz D, LaRusso N, Gores G, Tsuneyoshi M, Sugimachi K, Wands JR, de la Monte SM. Clinicopathological correlates of aspartyl(asparaginyl)beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev 2004; 28(5):313-8.
    View PubMed
  433. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol. 2003 Dec; 39 (6):978-83
    View PubMed
  434. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, Gores GJ. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology. 2003 Nov; 38 (5):1188-98
    View PubMed
  435. Janssen HLA, Higuchi H, Abdulkarim A, Gores GJ. Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol. 2003 Sep; 39(3):414-20.
    View PubMed
  436. Higuchi H, Gores GJ. Mechanisms of liver injury: an overview. Curr Mol Med. 2003 Sep; 3 (6):483-90
    View PubMed
  437. Peterson TE, Guicciardi ME, Gulati R, Kleppe LS, Mueske CS, Mookadam M, Sowa G, Gores GJ, Sessa WC, Simari RD. Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol. 2003 Sep 1; 23(9):1521-7. Epub 2003 Jun 19.
    View PubMed
  438. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003 Aug; 125 (2):437-43
    View PubMed
  439. Grambihler A, Higuchi H, Bronk SF, Gores GJ. cFLIP-L inhibits p38 MAPK activation: an additional anti-apoptotic mechanism in bile acid-mediated apoptosis. J Biol Chem. 2003 Jul 18; 278 (29):26831-7 Epub 2003 May 12
    View PubMed
  440. Canbay A, Guicciardi ME, Higuchi H, Feldstein A, Bronk SF, Rydzewski R, Taniai M, Gores GJ. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest. 2003 Jul; 112 (2):152-9
    View PubMed
  441. Werneburg NW, Yoon JH, Higuchi H, Gores GJ. Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol. 2003 Jul; 285 (1):G31-6 Epub 2003 Feb 26
    View PubMed
  442. Stadheim LM, O'Brien JF, Lindor KD, Gores GJ, McGill DB. Value of determining carbohydrate-deficient transferrin isoforms in the diagnosis of alcoholic liver disease. Mayo Clin Proc. 2003 Jun; 78(6):703-7.
    View PubMed
  443. Higuchi H, Gores GJ. Bile acid regulation of hepatic physiology - IV. Bile acids and death receptors. Am J Physiol Gastrointest Liver Physiol. 2003 May; 284(5):G734-8.
    View PubMed
  444. Gores GJ. Cholangiocarcinoma: Current concepts and insights. Hepatology. 2003 May; 37(5):961-9.
    View PubMed
  445. Decker GA, Gores GJ, Roberts LR. Tumor seeding complicating radiofrequency ablation of hepatocellular carcinoma. J Hepatol. 2003 May; 38 (5):692
    View PubMed
  446. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest. 2003 May; 83 (5):655-63
    View PubMed
  447. Yoon JH, Gores GJ. Diagnosis, Staging, and Treatment of Cholangiocarcinoma. Curr Treat Options Gastroenterol. 2003 Apr; 6 (2):105-112
    View PubMed
  448. Natori S, Higuchi H, Contreras P, Gores GJ. The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury. Liver Transpl. 2003 Mar; 9(3):278-84.
    View PubMed
  449. Leung TWT, Yu S, Johnson PJ, Geschwind J, Vogl TJ, Engelmann K, Gores GJ, Giovannini M, O'Grady J, Heneghan M, Stewart M, Orenberg EK, Thuluvath PJ. Phase II study of the efficacy and safety of cisplatin-epinephrine injectable gel administered to patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2003 Feb 15; 21(4):652-8.
    View PubMed
  450. Higuchi H, Yoon JH, Grambihler A, Werneburg N, Bronk SF, Gores GJ. Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis. J Biol Chem. 2003 Jan 3; 278 (1):454-61 Epub 2002 Oct 28
    View PubMed
  451. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology. 2003 Jan; 37(1):87-95.
    View PubMed
  452. Matsushita T, Yagi T, Hardin JA, Cragun JD, Crow FW, Bergen HR 3rd, Gores GJ, Nyberg SL. Apoptotic cell death and function of cryopreserved porcine hepatocytes in a bioartificial liver. Cell Transplant. 2003; 12 (2):109-21
    View PubMed
  453. Hassoun Z, Gores GJ. What surgeons should know about viral hepatitis and hepatocellular carcinoma. Surg Oncol Clin N Am. 2003 Jan; 12 (1):1-11, vii
    View PubMed
  454. Hassoun Z, Gores GJ. Treatment of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2003 Jan; 1: (1)10-8.
    View PubMed
  455. Sreekumar R, Wiessner RH, Gores GJ, Rosen CB, Charlton MR. Differential gene expression patterns in HCV-infected allografts during acute cellular rejection. Liver Transpl. 2003; 8:6.
  456. Holzknecht ZE, Kuypers KL, Plummer TB, Williams J, Bustos M, Gores GJ, Brunn GJ, Platt JL. Apoptosis and cellular activation in the pathogenesis of acute vascular rejection. Circ Res. 2002 Dec 13; 91 (12):1135-41
    View PubMed
  457. Sorom AJ, Nyberg SL, Gores GJ. Keratin, fas, and cryptogenic liver failure. Liver Transpl. 2002 Dec; 8 (12):1195-7
    View PubMed
  458. Johnson ME, Saenz JA, DaSilva AD, Uhl CB, Gores GJ. Effect of local anesthetic on neuronal cytoplasmic calcium and plasma membrane lysis (necrosis) in a cell culture model. Anesthesiology. 2002 Dec; 97 (6):1466-76
    View PubMed
  459. Yoon JH, Werneburg NW, Higuchi H, Canbay AE, Kaufmann SH, Akgul C, Edwards SW, Gores GJ. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res. 2002 Nov 15; 62 (22):6500-5
    View PubMed
  460. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem. 2002 Nov 15; 277 (46):44236-43 Epub 2002 Sept 05
    View PubMed
  461. Higuchi H, Bronk SF, Taniai M, Canbay A, Gores GJ. Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity. Journal of Pharmacology & Experimental Therapeutics. 2002 Nov; 303(2):461-7.
    View PubMed
  462. Werneburg NW, Guicciardi ME, Bronk SF, Gores GJ. Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol. 2002 Oct; 283 (4):G947-56
    View PubMed
  463. Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology. 2002 Oct; 123 (4):1090-8
    View PubMed
  464. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology. 2002 Oct; 123 (4):1323-30
    View PubMed
  465. Hassoun Z, Gores GJ, Rosen CB. Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. Surg Oncol Clin N Am. 2002 Oct; 11 (4):909-21
    View PubMed
  466. Nyberg SL, Matsushita T, Gores GJ, Hay JE, Wiesner RH, Pineda AA, Gastineau DA, Moore SB, Plevak DJ, Wijdicks EF, Piepgras DG, Platt JL, Rosen CB. The role of cell-based bioartificial liver therapy in the treatment of fulminant hepatic failure. Graft. 2002 Oct-Nov; 5(7):374-82.
  467. Yoon JH, Gores GJ. Death receptor-mediated apoptosis and the liver. J Hepatol. 2002 Sep; 37 (3):400-10
    View PubMed
  468. Guicciardi ME, Gores GJ. Bile acid-mediated hepatocyte apoptosis and cholestatic liver disease. Dig Liver Dis. 2002 Jun; 34 (6):387-92
    View PubMed
  469. Gores GJ. Yes, hepatocellular cancer does occur in primary biliary cirrhosis. Liver Transpl. 2002 Jun; 8(6):570-1.
    View PubMed
  470. Buckles DC, Lindor KD, Larusso NF, Petrovic LM, Gores GJ. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol. 2002 May; 97(5):1138-42.
    View PubMed
  471. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002 Apr; 122 (4):985-93
    View PubMed
  472. Torok NJ, Higuchi H, Bronk S, Gores GJ. Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9. Cancer Res. 2002 Mar 15; 62 (6):1648-53
    View PubMed
  473. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology. 2002 Mar; 35 (3):552-9
    View PubMed
  474. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci. 2002 Feb; 65(2):166-76.
    View PubMed
  475. Higuchi H, Miyoshi H, Bronk SF, Zhang H, Dean N, Gores GJ. Bid antisense attenuates bile acid-induced apoptosis and cholestatic liver injury. J Pharmacol Exp Ther. 2001 Dec; 299(3):866-73.
    View PubMed
  476. Guicciardi ME, Miyoshi H, Bronk SF, Gores GJ. Cathepsin B knockout mice are resistant to tumor necrosis factor-alpha-mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. Am J Pathol. 2001 Dec; 159 (6):2045-54
    View PubMed
  477. Gores GJ. Chemoembolization as a bridge to transplantation for hepatocellular carcinoma. Liver Transpl. 2001 Nov; 7: (11)998.
    View PubMed
  478. Higuchi H, Bronk SF, Takikawa Y, Werneburg N, Takimoto R, El-Deiry W, Gores GJ. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem. 2001 Oct 19; 276 (42):38610-8 Epub 2001 Aug 15
    View PubMed
  479. Menon KV, Gores GJ, Shah VH. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc. 2001 Oct; 76 (10):1021-9
    View PubMed
  480. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol. 2001 Sep; 281 (3):G626-34
    View PubMed
  481. Jaiswal M, LaRusso NF, Nishioka N, Nakabeppu Y, Gores GJ. Human Ogg1, a protein involved in the repair of 8-oxoguanine, is inhibited by nitric oxide. Cancer Res. 2001 Sep 1; 61(17):6388-93.
    View PubMed
  482. Higuchi H, Adachi M, Miura S, Gores GJ, Ishii H. The mitochondrial permeability transition contributes to acute ethanol-induced apoptosis in rat hepatocytes. Hepatology. 2001 Aug; 34(2):320-8.
    View PubMed
  483. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol. 2001 Jul; 35 (1):134-46
    View PubMed
  484. Gores GJ, Kaufmann SH. Is TRAIL hepatotoxic? Hepatology. 2001 Jul; 34(1):3-6.
    View PubMed
  485. Takikawa Y, Miyoshi H, Rust C, Roberts P, Siegel R, Mandal PK, Millikan RE, Gores GJ. The bile acid-activated phosphatidylinositol 3-kinase pathway inhibits Fas apoptosis upstream of bid in rodent hepatocytes. Gastroenterology. 2001 Jun; 120 (7):1810-7
    View PubMed
  486. Yagi T, Hardin JA, Valenzuela YM, Miyoshi H, Gores GJ, Nyberg SL. Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes. Hepatology. 2001 Jun; 33(6):1432-40.
    View PubMed
  487. Chen XM, Levine SA, Splinter PL, Tietz PS, Ganong AL, Jobin C, Gores GJ, Paya CV, LaRusso NF. Cryptosporidium parvum activates nuclear factor kappaB in biliary epithelia preventing epithelial cell apoptosis. Gastroenterology. 2001 Jun; 120 (7):1774-83
    View PubMed
  488. Souto EO, Miyoshi H, Dubois RN, Gores GJ. Kupffer cell-derived cyclooxygenase-2 regulates hepatocyte Bcl-2 expression in choledocho-venous fistula rats. Am J Physiol Gastrointest Liver Physiol. 2001 May; 280 (5):G805-11
    View PubMed
  489. Torok N, Gores GJ. Cholangiocarcinoma. Semin Gastrointest Dis. 2001 Apr; 12: (2)125-32.
    View PubMed
  490. Rumalla A, Baron TH, Wang KK, Gores GJ, Stadheim LM, de Groen PC. Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc. 2001 Apr; 53: (4)500-4.
    View PubMed
  491. Kaya M, de Groen PC, Angulo P, Nagorney DM, Gunderson LL, Gores GJ, Haddock MG, Lindor KD. Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. Am J Gastroenterol. 2001 Apr; 96(4):1164-9.
    View PubMed
  492. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. Hepatology. 2001 Apr; 33(4):1009-13.
    View PubMed
  493. Miyoshi H, Rust C, Guicciardi ME, Gores GJ. NF-kappaB is activated in cholestasis and functions to reduce liver injury. Am J Pathol. 2001 Mar; 158 (3):967-75
    View PubMed
  494. Keegan MT, Kamath GS, Vasdev GM, Findlay JY, Gores GJ, Steers JL, Plevak DJ. Liver transplantation for massive hepatic haemangiomatosis causing restrictive lung disease. Br J Anaesth. 2001 Mar; 86 (3):431-4
    View PubMed
  495. Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, Gores GJ. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol. 2001 Feb; 34 (2):248-53
    View PubMed
  496. Rust C, Gores GJ. Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies. Clin Liver Dis. 2001 Feb; 5 (1):161-73
    View PubMed
  497. Jaiswal M, LaRusso NF, Shapiro RA, Billiar TR, Gores GJ. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology. 2001 Jan; 120 (1):190-9
    View PubMed
  498. Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res. 2000 Nov 15; 60(22):6396-402.
    View PubMed
  499. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, Kaufmann SH, Gores GJ. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest. 2000 Nov; 106 (9):1127-37
    View PubMed
  500. Kaufmann SH, Gores GJ. Apoptosis in cancer: cause and cure. Bioessays. 2000 Nov; 22 (11):1007-17
    View PubMed
  501. Gores GJ. Early detection and treatment of cholangiocarcinoma. Liver Transpl. 2000 Nov; 6(6 Suppl 2):S30-4.
    View PubMed
  502. Guicciardi ME, Gores GJ. Dying in Fas traffic. Hepatology. 2000 Aug; 32 (2):439-40
    View PubMed
  503. Rust C, Karnitz LM, Paya CV, Moscat J, Simari RD, Gores GJ. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem. 2000 Jun 30; 275 (26):20210-6
    View PubMed
  504. Sodeman T, Bronk SF, Roberts PJ, Miyoshi H, Gores GJ. Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. Am J Physiol Gastrointest Liver Physiol. 2000 Jun; 278 (6):G992-9
    View PubMed
  505. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 2000 May; 6(3):309-16.
    View PubMed
  506. Rust C, Gores GJ. Apoptosis and liver disease. Am J Med. 2000 May; 108 (7):567-74
    View PubMed
  507. Poggio JL, Rowland CM, Gores GJ, Nagorney DM, Donohue JH. A comparison of laparoscopic and open cholecystectomy in patients with compensated cirrhosis and symptomatic gallstone disease. Surgery. 2000 Apr; 127 (4):405-11
    View PubMed
  508. Nyberg SL, Hardin JA, Matos LE, Rivera DJ, Misra SP, Gores GJ. Cytoprotective influence of ZVAD-fmk and glycine on gel-entrapped rat hepatocytes in a bioartificial liver. Surgery. 2000 Apr; 127 (4):447-55
    View PubMed
  509. Ribeiro A, Nagorney DM, Gores GJ. Localized hepatocellular carcinoma: therapeutic options. Curr Gastroenterol Rep. 2000 Feb; 2 (1):72-81
    View PubMed
  510. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000 Jan; 95 (1):204-7
    View PubMed
  511. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000 Jan 1; 60 (1):184-90
    View PubMed
  512. Jaiswal M., LaRusso NF, Gores GJ. Cholangiocarcinoma, pro-inflammatory cyokines. Cancer Research Alert. 2000; 1:141-3.
  513. Gores GJ. Mechanisms of cell injury and death in cholestasis and hepatoprotection by ursodeoxycholic acid. J Hepatol. 2000; 32(Suppl 2):11-13.
    View PubMed
  514. Ribeiro A, Bronk SF, Roberts PJ, Urrutia R, Gores GJ. The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. Hepatology. 1999 Dec; 30: (6)1490-7.
    View PubMed
  515. Lazaridis KN, Gores GJ. Liver mass in a patient with primary sclerosing cholangitis. J Hepatol. 1999 Dec; 31 (6):1086
    View PubMed
  516. Que FG, Phan VA, Phan VH, Celli A, Batts K, LaRusso NF, Gores GJ. Cholangiocarcinomas express Fas ligand and disable the Fas receptor. Hepatology. 1999 Dec; 30 (6):1398-404
    View PubMed
  517. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation. 1999 Nov 27; 68 (10):1517-25
    View PubMed
  518. Komuro A, Hodge DO, Gores GJ, Bourne WM. Cell death during corneal storage at 4 degrees C. Invest Ophthalmol Vis Sci. 1999 Nov; 40: (12)2827-32.
    View PubMed
  519. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, Poterucha JJ, Rosen CB, Gores GJ, LaRusso NF, Krom RA. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology. 1999 Nov; 30 (5):1121-7
    View PubMed
  520. Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology. 1999 Nov; 30 (5):1128-33
    View PubMed
  521. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999 Oct 28; 341 (18):1368-78
    View PubMed
  522. Patel T, Steer CJ, Gores GJ. Apoptosis and the liver: A mechanism of disease, growth regulation, and carcinogenesis. Hepatology. 1999 Sep; 30(3):811-5.
    View PubMed
  523. Chen XM, Gores GJ, Paya CV, LaRusso NF. Cryptosporidium parvum induces apoptosis in biliary epithelia by a Fas/Fas ligand-dependent mechanism. Am J Physiol. 1999 Sep; 277 (3):G599-608
    View PubMed
  524. Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology. 1999 Sep; 117 (3):669-77
    View PubMed
  525. Natori S, Selzner M, Valentino KL, Fritz LC, Srinivasan A, Clavien PA, Gores GJ. Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism. Transplantation. 1999 Jul 15; 68 (1):89-96
    View PubMed
  526. Que FG, Phan VA, Phan VH, LaRusso NF, Gores GJ. GUDC inhibits cytochrome c release from human cholangiocyte mitochondria. J Surg Res. 1999 May 15; 83 (2):100-5
    View PubMed
  527. Harnois DM, Steers J, Andrews JC, Rubin JC, Pitot HC, Burgart L, Wiesner RH, Gores GJ. Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver Transpl Surg. 1999 May; 5(3):192-9.
    View PubMed
  528. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, Hay JE, Gores GJ, Charlton MR, Ludwig J, Poterucha JJ, Steers JL, Krom RA. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999 Apr; 29 (4):1050-6
    View PubMed
  529. Park J, Gores GJ, Patel T. Lipopolysaccharide induces cholangiocyte proliferation via an interleukin-6-mediated activation of p44/p42 mitogen-activated protein kinase. Hepatology. 1999 Apr; 29 (4):1037-43
    View PubMed
  530. Arora AS, Nichols JC, DeBernardi M, Steers JL, Krom RA, Gores GJ. Glycine rinse protects against liver injury during transplantation. Transplant Proc. 1999 Feb-Mar; 31 (1-2):505-6
    View PubMed
  531. Rivera DJ, Gores GJ, Misra SP, Hardin JA, Nyberg SL. Apoptosis by gel-entrapped hepatocytes in a bioartificial liver. Transplant Proc. 1999 Feb-Mar; 31 (1-2):671-3
    View PubMed
  532. Faubion WA, Gores GJ. Death receptors in liver biology and pathobiology. Hepatology. 1999 Jan; 29(1):1-4.
    View PubMed
  533. Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ, Svingen PA, Kaufmann SH, Gores GJ. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest. 1999 Jan; 103 (1):137-45
    View PubMed
  534. Nyberg SL, Matos LE, Hardin JA, Gores GJ. Caspase inhibition by ZVAD-fmk reduces apoptotic death of hepatocytes in a bioartificial liver. Surgical Forum. 1999; L:5-7.
  535. Roberts LR, Adjei PN, Gores GJ. Cathepsins as effector proteases in hepatocyte apoptosis. Cell Biochem Biophys. 1999; 30(1):71-88.
    View PubMed
  536. Guicciardi ME, Gores GJ. Is ursodeoxycholate an antiapoptotic drug? Hepatology. 1998 Dec; 28(6):1721-3.
    View PubMed
  537. Kitabayashi K, Gores GJ, Krom RA. Arterial ketone body ratio in clinical liver transplantation. Transplant Proc. 1998 Dec; 30 (8):4356-9
    View PubMed
  538. Celli A, Que FG, Gores GJ, LaRusso NF. Glutathione depletion is associated with decreased Bcl-2 expression and increased apoptosis in cholangiocytes. Am J Physiol. 1998 Oct; 275 (4):G749-57
    View PubMed
  539. Jones B, Roberts PJ, Faubion WA, Kominami E, Gores GJ. Cystatin A expression reduces bile salt-induced apoptosis in a rat hepatoma cell line. Am J Physiol. 1998 Oct; 275 (4):G723-30
    View PubMed
  540. Celli A, Que FG, Gores GJ, LaRusso NF. Glutathione depletion is associated with decreased Bcl-2 expression and increased apoptosis in cholangiocytes. Am J Physiol Gastrointest Liver Physiol. 1998 Oct 1; 275 (4):G749-G757
    View PubMed
  541. Jones B, Roberts PJ, Faubion WA, Kominami E, Gores GJ. Cystatin A expression reduces bile salt-induced apoptosis in a rat hepatoma cell line. Am J Physiol Gastrointest Liver Physiol. 1998 Oct 1; 275 (4):G723-G730
    View PubMed
  542. Lieser MJ, Park J, Natori S, Jones BA, Bronk SF, Gores GJ. Cholestasis confers resistance to the rat liver mitochondrial permeability transition. Gastroenterology. 1998 Sep; 115(3):693-701.
    View PubMed
  543. Ribeiro A, Burgart LJ, Nagorney DM, Gores GJ. Management of liver adenomatosis: results with a conservative surgical approach. Liver Transpl Surg. 1998 Sep; 4 (5):388-98
    View PubMed
  544. Gores GJ, Miyoshi H, Botla R, Aguilar HI, Bronk SF. Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: a potential role for mitochondrial proteases. Biochim Biophys Acta. 1998 Aug 10; 1366 (1-2):167-75
    View PubMed
  545. Karnes WE Jr, Weller SG, Adjei PN, Kottke TJ, Glenn KS, Gores GJ, Kaufmann SH. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology. 1998 May; 114 (5):930-9
    View PubMed
  546. Jones BA, Gores GJ. Hepatobiliary malignancy. Clin Liver Dis. 1998 May; 2 (2):437-49, xi-xii
    View PubMed
  547. Miyoshi H, Gores GJ. Apoptosis and the liver: relevance for the hepato-biliary-pancreatic surgeon. J Hepatobiliary Pancreat Surg. 1998; 5 (4):409-15
    View PubMed
  548. Gores GJ. Apoptosis and hepatobiliary disease with a focus on fulminant hepatic failure. Acta Hepatologica Japonica. 1998; 55:851-3.
  549. Patel T, Patel T, Gores GJ. Apoptosis in liver transplantation: a mechanism contributing to immune modulation, preservation injury, neoplasia, and viral disease. Liver Transpl Surg. 1998 Jan; 4 (1):42-50
    View PubMed
  550. Patel T, Roberts LR, Jones BA, Gores GJ. Dysregulation of apoptosis as a mechanism of liver disease: an overview. Semin Liver Dis. 1998; 18(2):105-14.
    View PubMed
  551. Jones BA, Gores GJ. Physiology and pathophysiology of apoptosis in epithelial cells of the liver, pancreas, and intestine. Am J Physiol. 1997 Dec; 273 (6):G1174-88
    View PubMed
  552. Jones BA, Gores GJ. Physiology and pathophysiology of apoptosis in epithelial cells of the liver, pancreas, and intestine. Am J Physiol Gastrointest Liver Physiol. 1997 Dec 1; 273 (6):G1174-G1188
    View PubMed
  553. Roberts LR, Kurosawa H, Bronk SF, Fesmier PJ, Agellon LB, Leung WY, Mao F, Gores GJ. Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes. Gastroenterology. 1997 Nov; 113 (5):1714-26
    View PubMed
  554. Harnois DM, Que FG, Celli A, LaRusso NF, Gores GJ. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology. 1997 Oct; 26 (4):884-90
    View PubMed
  555. Harnois DM, Gores GJ, Ludwig J, Steers JL, LaRusso NF, Wiesner RH. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol. 1997 Sep; 27 (3):512-6
    View PubMed
  556. Kurosawa H, Que FG, Roberts LR, Fesmier PJ, Gores GJ. Hepatocytes in the bile duct-ligated rat express Bcl-2. Am J Physiol. 1997 Jun; 272 (6 Pt 1):G1587-93
    View PubMed
  557. Tachibana I, Imoto M, Adjei PN, Gores GJ, Subramaniam M, Spelsberg TC, Urrutia R. Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. J Clin Invest. 1997 May 15; 99 (10):2365-74
    View PubMed
  558. Jones BA, Rao YP, Stravitz RT, Gores GJ. Bile salt-induced apoptosis of hepatocytes involves activation of protein kinase C. Am J Physiol. 1997 May; 272 (5 Pt 1):G1109-15
    View PubMed
  559. Arora AS, Jones BJ, Patel TC, Bronk SF, Gores GJ. Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat. Hepatology. 1997 Apr; 25(4):958-63.
    View PubMed
  560. Aguilar HI, Steers JL, Wiesner RH, Krom RA, Gores GJ. Enhanced liver calpain protease activity is a risk factor for dysfunction of human liver allografts. Transplantation. 1997 Feb 27; 63 (4):612-4
    View PubMed
  561. Roberts LR, Bronk SF, Gores GJ. Effector proteases in bile salt-induced hepatocyte apoptosis. Bile Acids in Hepatobiliary Diseases--Basic Research and Clinical Applications Falk Symposium Series. 1997; 93:265-71.
  562. Roberts LR, Gores GJ. The role of hepatocyte apoptosis in liver growth regulation and disease. Prog Liver Dis. 1997; 15:57-83.
  563. Zeid IM, Bronk SF, Fesmier PJ, Gores GJ. Cytoprotection by fructose and other ketohexoses during bile salt-induced apoptosis of hepatocytes. Hepatology. 1997 Jan; 25(1):81-6.
    View PubMed
  564. Patel T, Gores GJ. Inhibition of bile-salt-induced hepatocyte apoptosis by the antioxidant lazaroid U83836E. Toxicol Appl Pharmacol. 1997 Jan; 142(1):116-22.
    View PubMed
  565. Que FG, Gores GJ, LaRusso NF. Development and initial application of an in vitro model of apoptosis in rodent cholangiocytes. Am J Physiol. 1997 Jan; 272 (1 Pt 1):G106-15
    View PubMed
  566. Que F, Gores GJ. Apoptosis and the gastrointestinal system. Adv Pharmacol. 1997; 41:409-28
    View PubMed
  567. Marsman WA, Moore SB, Kondo M, Bundy KL, Gores GJ, Wiesner RH, Krom RA. Do cold agglutinins have any impact on the outcome of liver transplantation? Transplantation. 1996 Dec 15; 62 (11):1673-6
    View PubMed
  568. Adjei PN, Kaufmann SH, Leung WY, Mao F, Gores GJ. Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32. J Clin Invest. 1996 Dec 1; 98 (11):2588-96
    View PubMed
  569. Marsman WA, Wiesner RH, Rodriguez L, Batts KP, Porayko MK, Hay JE, Gores GJ, Krom RA. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation. 1996 Nov 15; 62 (9):1246-51
    View PubMed
  570. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996 Jun; 23(6):1464-7.
    View PubMed
  571. Arora AS, de Groen PC, Croall DE, Emori Y, Gores GJ. Hepatocellular carcinoma cells resist necrosis during anoxia by preventing phospholipase-mediated calpain activation. J Cell Physiol. 1996 Jun; 167 (3):434-42
    View PubMed
  572. Eghbali-Fatourechi G, Sieck GC, Prakash YS, Maercklein P, Gores GJ, Fitzpatrick LA. Type I procollagen production and cell proliferation is mediated by transforming growth factor-beta in a model of hepatic fibrosis. Endocrinology. 1996 May; 137(5):1894-903.
    View PubMed
  573. Patel T, Patel T, Gores GJ, Kaufmann SH. The role of proteases during apoptosis. FASEB J. 1996 Apr; 10 (5):587-97
    View PubMed
  574. Que FG, Gores GJ. Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist. Gastroenterology. 1996 Apr; 110 (4):1238-43
    View PubMed
  575. Ziser A, Forstrom LA, Plevak DJ, Sanchez-Urdazpal L, Gores GJ, Wiesner RH, Batts KP, Krom RA. Granulocyte accumulation in the transplanted liver does not correlate with clinical and histologic evidence of dysfunction. Invest Radiol. 1996 Mar; 31 (3):132-7
    View PubMed
  576. Lindor KD, Jorgensen RA, Anderson ML, Gores GJ, Hofmann AF, LaRusso NF. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol. 1996 Mar; 91(3):511-5.
    View PubMed
  577. Arora AS, de Groen P, Emori Y, Gores GJ. A cascade of degradative hydrolase activity contributes to hepatocyte necrosis during anoxia. Am J Physiol. 1996 Feb; 270 (2 Pt 1):G238-45
    View PubMed
  578. Arora AS, Gores GJ. The role of metals in ischemia/reperfusion injury of the liver. Semin Liver Dis. 1996 Feb; 16(1):31-8.
    View PubMed
  579. Aguilar HI, Botla R, Arora AS, Bronk SF, Gores GJ. Induction of the mitochondrial permeability transition by protease activity in rats: a mechanism of hepatocyte necrosis. Gastroenterology. 1996 Feb; 110 (2):558-66
    View PubMed
  580. Johnson ME, Johnson ME, Sill JC, Uhl CB, Halsey TJ, Gores GJ. Effect of volatile anesthetics on hydrogen peroxide-induced injury in aortic and pulmonary arterial endothelial cells. Anesthesiology. 1996 Jan; 84 (1):103-16
    View PubMed
  581. Gores GJ. Gastrointestinal Cancers: Biology, Diagnosis, and Therapy, edited by Rustgi A.K. Reviewed in Gastroenterology. 1996; 110:1321-2.
  582. Gores GJ. Atlas of Clinical Hepatology, edited by Gitilin N. and Strauss R.M. Reviewed in Mayo Clinic Procedures. 1996; 71:723.
  583. Ludwig J, Gores GJ. Infarct cavities in a hepatic allograft. (Note). N Engl J Med. 1995 Oct 26; 333:1117.
    View PubMed
  584. Lindor KD, Dickson ER, Jorgensen RA, Anderson ML, Wiesner RH, Gores GJ, Lange SM, Rossi SS, Hofmann AF, Baldus WP. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology. 1995 Oct; 22 (4 Pt 1):1158-62
    View PubMed
  585. Patel T, Arora A, Gores GJ. A fluorometric assay for quantitating DNA strand breaks during apoptosis. Anal Biochem. 1995 Aug 10; 229(2):229-35.
    View PubMed
  586. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Rossi SS, Hofmann AF, Gores GJ, Phillips SF. Fecal bile acids, short-chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis. Dig Dis Sci. 1995 Jul; 40 (7):1474-83
    View PubMed
  587. Tan CK, Podila PV, Taylor JE, Nagorney DM, Wiseman GA, Gores GJ, LaRusso NF. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology. 1995 Jun; 108 (6):1908-16
    View PubMed
  588. Patel T, Patel T, Gores GJ. Apoptosis and hepatobiliary disease. Hepatology. 1995 Jun; 21 (6):1725-41
    View PubMed
  589. Textor SC, Burnett JC Jr, Romero JC, Canzanello VJ, Taler SJ, Wiesner R, Porayko M, Wiesner R, Krom R, Gores G, Krom R, Gores G, Hay E, Hay E. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int. 1995 May; 47 (5):1426-33
    View PubMed
  590. Kwo P, Patel T, Bronk SF, Gores GJ. Nuclear serine protease activity contributes to bile acid-induced apoptosis in hepatocytes. Am J Physiol. 1995 Apr; 268 (4 Pt 1):G613-21
    View PubMed
  591. Botla R, Spivey JR, Aguilar H, Bronk SF, Gores GJ. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J Pharmacol Exp Ther. 1995 Feb; 272(2):930-8.
    View PubMed
  592. Sandborn WJ, Lawson GM, Cody TJ, Porayko MK, Hay JE, Gores GJ, Steers JL, Krom RA, Wiesner RH. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology. 1995 Jan; 21(1):70-6.
    View PubMed
  593. Rosser BG, Gores GJ. Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology. 1995 Jan; 108 (1):252-75
    View PubMed
  594. Marks DL, Gores GJ, LaRusso NF. Hepatic Processing of Peptides American Chemical Society. 1995; 0: 0.
  595. Gores GJ. Hepatobiliary Malignancy: Its Multidisciplinary Management, edited by Terblanche J. Reviewed in Gastroenterology. 1995; 109:329.
  596. Patel T, Bronk SF, Gores GJ. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J Clin Invest. 1994 Dec; 94 (6):2183-92
    View PubMed
  597. Ninova DI, Wiesner RH, Gores GJ, Harrison JM, Krom RA, Homburger HA. Soluble T lymphocyte markers in the diagnosis of cellular rejection and cytomegalovirus hepatitis in liver transplant recipients. J Hepatol. 1994 Dec; 21 (6):1080-5
    View PubMed
  598. Wiesner RH, Ludwig J, Krom RA, Steers JL, Porayko MK, Gores GJ, Hay JE. Treatment of early cellular rejection following liver transplantation with intravenous methylprednisolone. The effect of dose on response. Transplantation. 1994 Nov 15; 58 (9):1053-6
    View PubMed
  599. Spivey JR, Jorgensen RA, Gores GJ, Lindor KD. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 1994 Nov; 89 (11):2028-32
    View PubMed
  600. Eghbali-Fatourechi G, Conover CA, Sieck GC, Gores GJ, Fitzpatrick LA. Secretion of insulin-like growth factor binding protein-1 from individual hepatocytes. Res Commun Mol Pathol Pharmacol. 1994 Sep; 85 (3):243-59
    View PubMed
  601. Gates LK Jr, Wiesner RH, Krom RA, Steers J, Gores GJ, Hay JE, Porayko MK. Etiology and incidence of unconjugated hyperbilirubinemia after orthotopic liver transplantation. Am J Gastroenterol. 1994 Sep; 89 (9):1541-3
    View PubMed
  602. Johnson ME, Johnson ME, Gores GJ, Uhl CB, Sill JC. Cytosolic free calcium and cell death during metabolic inhibition in a neuronal cell line. J Neurosci. 1994 Jul; 14 (7):4040-9
    View PubMed
  603. Fujii Y, Johnson ME, Johnson ME, Gores GJ. Mitochondrial dysfunction during anoxia/reoxygenation injury of liver sinusoidal endothelial cells. Hepatology. 1994 Jul; 20 (1 Pt 1):177-85
    View PubMed
  604. Tan CK, Gores GJ, Steers JL, Porayko MK, Hay JE, Rakela J, Wiesner RH, Krom RA. Orthotopic liver transplantation for preoperative early-stage hepatocellular carcinoma. Mayo Clin Proc. 1994 Jun; 69 (6):509-14
    View PubMed
  605. Sandborn WJ, Hay JE, Porayko MK, Gores GJ, Steers JL, Krom RA, Wiesner RH. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology. 1994 Apr; 19(4):925-32.
    View PubMed
  606. Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc. 1994 Feb; 69 (2):105-11
    View PubMed
  607. Nichols JC, Bronk SF, Mellgren RL, Gores GJ. Inhibition of nonlysosomal calcium-dependent proteolysis by glycine during anoxic injury of rat hepatocytes. Gastroenterology. 1994 Jan; 106 (1):168-76
    View PubMed
  608. Gores GJ. Immunology of Liver Transplantation, edited by Neuberger J. and Adams A. Reviewed in Mayo Clinic Proceedings. 1994; 69:301.
  609. Textor SC, Schwartz L, Wilson DJ, Wiesner R, Romero JC, Augustine J, Kos P, Hay E, Gores G, Dickson ER. Systemic and renal effects of nifedipine in cyclosporine-associated hypertension. Hypertension. 1994 Jan; 23 (1 Suppl):I220-4
    View PubMed
  610. Rosser BG, Powers SP, Gores GJ. Calpain activity increases in hepatocytes following addition of ATP. Demonstration by a novel fluorescent approach. J Biol Chem. 1993 Nov 5; 268 (31):23593-600
    View PubMed
  611. Roberts SK, Kuntz SM, Gores GJ, LaRusso NF. Regulation of bicarbonate-dependent ductular bile secretion assessed by lumenal micropuncture of isolated rodent intrahepatic bile ducts. Proc Natl Acad Sci U S A. 1993 Oct 1; 90 (19):9080-4
    View PubMed
  612. Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE Jr. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc. 1993 Sep; 68 (9):874-9
    View PubMed
  613. Noack K, Bronk SF, Kato A, Gores GJ. The greater vulnerability of bile duct cells to reoxygenation injury than to anoxia. Implications for the pathogenesis of biliary strictures after liver transplantation. Transplantation. 1993 Sep; 56 (3):495-500
    View PubMed
  614. Sanchez-Urdazpal L, Batts KP, Gores GJ, Moore SB, Sterioff S, Wiesner RH, Krom RA. Increased bile duct complications in liver transplantation across the ABO barrier. Ann Surg. 1993 Aug; 218 (2):152-8
    View PubMed
  615. Spivey JR, Bronk SF, Gores GJ. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J Clin Invest. 1993 Jul; 92 (1):17-24
    View PubMed
  616. Gores GJ. Liver transplantation for malignant disease. Gastroenterol Clin North Am. 1993 Jun; 22(2):285-99.
    View PubMed
  617. Textor SC, Wiesner R, Wilson DJ, Wiesner R, Porayko M, Romero JC, Burnett JC Jr, Gores G, Hay E, Gores G, Hay E, Dickson ER, Krom RA. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation. 1993 Jun; 55 (6):1332-9
    View PubMed
  618. Bronk SF, Powers SP, Gores GJ. Dynamic measurements of intracellular aminopeptidase activity in hepatocytes using multiparameter digitized video fluorescent microscopy. Anal Biochem. 1993 May 1; 210 (2):219-25
    View PubMed
  619. Dawson TL, Gores GJ, Nieminen AL, Herman B, Lemasters JJ. Mitochondria as a source of reactive oxygen species during reductive stress in rat hepatocytes. Am J Physiol. 1993 Apr; 264(4 Pt 1):C961-7.
    View PubMed
  620. Bronk SF, Gores GJ. pH-dependent nonlysosomal proteolysis contributes to lethal anoxic injury of rat hepatocytes. Am J Physiol. 1993 Apr; 264 (4 Pt 1):G744-51
    View PubMed
  621. Sanchez-Urdazpal L, Gores GJ, Ward EM, Maus TP, Buckel EG, Steers JL, Wiesner RH, Krom RA. Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation. Hepatology. 1993 Apr; 17 (4):605-9
    View PubMed
  622. Wiesner RH, Porayko MK, Wahlstrom HE, Gores GJ, Kamath PS, Hay JE, Krom RA. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. Transplant Proc. 1993 Apr; 25 (2):1791-3
    View PubMed
  623. Ferguson DM, Gores GJ, Bronk SF, Krom RA. An increase in cytosolic protease activity during liver preservation. Inhibition by glutathione and glycine. Transplantation. 1993 Mar; 55 (3):627-33
    View PubMed
  624. Sanchez-Urdazpal L, Gores GJ, Ward EM, Hay E, Buckel EG, Wiesner RH, Krom RA. Clinical outcome of ischemic-type biliary complications after liver transplantation. Transplant Proc. 1993 Feb; 25(1 Pt 2):1107-9.
    View PubMed
  625. Sanchez-Urdazpal L, Gores GJ, Lemasters JJ, Thurman RG, Steers JL, Wahlstrom HE, Hay EI, Porayko MK, Wiesner RH, Krom RA. Carolina rinse solution decreases liver injury during clinical liver transplantation. Transplant Proc. 1993 Feb; 25(1 Pt 2):1574-5.
    View PubMed
  626. Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Wahlstrom HE, Sanchez-Urdazpal L, Richards T, Crotty P, Beaver S. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients. Transplant Proc. 1993 Feb; 25 (1 Pt 1):665-8
    View PubMed
  627. Lemasters JJ, Nieminen AL, Chacon E, Imberti R, Gores GJ, Reece JM, Herman B. Use of fluorescent probes to monitor mitochondrial membrane potential in isolated mitochondria, cell suspensions, and cultures cells. Mitochondrial Dysfunction: Methods In Toxicology. 1993; 2:404-415.
  628. Gores GJ, Krom RAF. Recent progress in liver transplantation for fulminant hepatic failure. Acta Hepatologica Japonica. 1993; 34:350-355.
  629. Wiesner RH, Porayko MK, Dickson ER, Gores GJ, LaRusso NF, Hay JE, Wahlstrom HE, Krom RA. Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology. 1992 Nov; 16(5):1290-9.
    View PubMed
  630. Kato A, Gores GJ, LaRusso NF. Secretin stimulates exocytosis in isolated bile duct epithelial cells by a cyclic AMP-mediated mechanism. J Biol Chem. 1992 Aug 5; 267 (22):15523-9
    View PubMed
  631. Nieminen AL, Gores GJ, Bond JM, Imberti R, Herman B, Lemasters JJ. A novel cytotoxicity screening assay using a multiwell fluorescence scanner. Toxicology & Applied Pharmacology. 1992 Aug; 115(2):147-55.
    View PubMed
  632. Sanchez-Urdazpal L, Gores GJ, Ward EM, Maus TP, Wahlstrom HE, Moore SB, Wiesner RH, Krom RA. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology. 1992 Jul; 16 (1):49-53
    View PubMed
  633. Dickson RC, Bronk SF, Gores GJ. Glycine cytoprotection during lethal hepatocellular injury from adenosine triphosphate depletion. Gastroenterology. 1992 Jun; 102 (6):2098-107
    View PubMed
  634. Spivey JR, Gores GJ. Risk factors and screening for hepatocellular carcinoma. Compr Ther. 1992 Jun; 18(6):5-9.
    View PubMed
  635. Groskreutz JL, Bronk SF, Gores GJ. Ruthenium red delays the onset of cell death during oxidative stress of rat hepatocytes. Gastroenterology. 1992 Mar; 102 (3):1030-8
    View PubMed
  636. Sanchez-Urdazpal L, Gores GJ, Lemasters JJ, Thurman RG, Steers JL, Wahlstrom HE, Hay EI, Porayko MK, Wiesner RH, Krom RAF. Carolina rinse solution decreases injury during clinical liver transplantation. Transplant Proc. 1992 Feb; 25(Suppl 1):1574-1575.
  637. Sanchez-Urdazpal L, Gores GJ, Ferguson DM, Krom RA. Improved liver preservation with addition of iloprost to Eurocollins and University of Wisconsin storage solutions. Transplantation. 1991 Dec; 52(6):1105-7.
    View PubMed
  638. Bronk SF, Gores GJ. Efflux of protons from acidic vesicles contributes to cytosolic acidification of hepatocytes during ATP depletion. Hepatology. 1991 Oct; 14 (4 Pt 1):626-33
    View PubMed
  639. Bronk SF, Gores GJ. Acidosis protects against lethal oxidative injury of liver sinusoidal endothelial cells. Hepatology. 1991 Jul; 14 (1):150-7
    View PubMed
  640. Takei Y, Marzi I, Gao WS, Gores GJ, Lemasters JJ, Thurman RG. Leukocyte adhesion and cell death following orthotopic liver transplantation in the rat. Transplantation. 1991 May; 51(5):959-65.
    View PubMed
  641. van Hoek B, Wiesner RH, Ludwig J, Gores GJ, Moore B, Krom RA. Combination immunosuppression with azathioprine reduces the incidence of ductopenic rejection and vanishing bile duct syndrome after liver transplantation. Transplant Proc. 1991 Feb; 23 (1 Pt 2):1403-5
    View PubMed
  642. Wahlstrom HE, Cooper J, Gores G, Rosen C, Wiesner R, Krom RA. Survival after liver transplantation in diabetics. Transplant Proc. 1991 Feb; 23(1 Pt 2):1565-6.
    View PubMed
  643. Currin RT, Gores GJ, Thurman RG, Lemasters JJ. Protection by acidotic pH against anoxic cell killing in perfused rat liver: evidence for a pH paradox. FASEB J. 1991 Feb; 5(2):207-10.
    View PubMed
  644. Ferguson DM, Gores GJ, Ludwig J, Krom RA. UW solution protects against reperfusion injury by inhibiting lipid peroxidation. Transplant Proc. 1991 Feb; 23(1 Pt 2):1552-3.
    View PubMed
  645. Kost LJ, Gores GJ, Sayles JM, Miller LJ, Lemasters JJ, Herman B, LaRusso NF. Lack of metabolic effects of cholecystokinin on hepatocytes. Hepatology. 1990 Aug; 12 (2):301-5
    View PubMed
  646. Marzi I, Takei Y, Knee J, Menger M, Gores GJ, Buhren V, Trentz O, Lemasters JJ, Thurman RG. Assessment of reperfusion injury by intravital fluorescence microscopy following liver transplantation in the rat. Transplant Proc. 1990 Aug; 22(4):2004-5.
    View PubMed
  647. Gores GJ, Ferguson DM, Ludwig J, Steffen R, Krom RA. Effect of acidosis during cold ischemic storage on liver viability following transplantation in the rat. Transplant Proc. 1990 Apr; 22(2):488-9.
    View PubMed
  648. Nieminen AL, Dawson TL, Gores GJ, Kawanishi T, Herman B, Lemasters JJ. Protection by acidotic pH and fructose against lethal injury to rat hepatocytes from mitochondrial inhibitors, ionophores and oxidant chemicals. Biochem Biophys Res Commun. 1990 Mar 16; 167(2):600-6.
    View PubMed
  649. Lemasters JJ, Gores GJ, Nieminen AL, Dawson TL, Wray BE, Herman B. Multiparameter digitized video microscopy of toxic and hypoxic injury in single cells. Environ Health Perspect. 1990 Mar; 84:83-94.
    View PubMed
  650. Nieminen AL, Gores GJ, Dawson TL, Herman B, Lemasters JJ. Toxic injury from mercuric chloride in rat hepatocytes. J Biol Chem. 1990 Feb 5; 265(4):2399-408.
    View PubMed
  651. Herman B, Gores GJ, Nieminen AL, Kawanishi T, Harman A, Lemasters JJ. Calcium and pH in anoxic and toxic injury. Crit Rev Toxicol. 1990; 21(2):127-48.
    View PubMed
  652. Gores GJ, Herman B, Lemasters JJ. Plasma membrane bleb formation and rupture a common feature of hepatocellular injury. Hepatology. 1990; 11:690-698.
    View PubMed
  653. Gores GJ, Kost LJ, Miller LJ, LaRusso NF. Processing of cholecystokinin by isolated liver cells. Am J Physiol. 1989 Aug; 257 (2 Pt 1):G242-8
    View PubMed
  654. Gores GJ, Flarsheim CE, Dawson TL, Nieminen AL, Herman B, Lemasters JJ. Swelling, reductive stress, and cell death during chemical hypoxia in hepatocytes. Am J Physiol. 1989 Aug; 257(2 Pt 1):C347-54.
    View PubMed
  655. Gores GJ, Wiesner RH, Dickson ER, Zinsmeister AR, Jorgensen RA, Langworthy A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology. 1989 Jun; 96 (6):1552-9
    View PubMed
  656. Bronk SG, Gores GJ. Sinusoidal endothelial cells are more susceptible to oxidative than to hypoxic cell injury. Hepatology. 1989; 10:612.
  657. Gores GJ, Nieminen AL, Wray BE, Herman B, Lemasters JJ. Intracellular PH during chemical hypoxia in cultured rat hepatocytes protection by intracellular acidosis against the onset of cell death. J Clin Invest. 1989; 83:388-396.
    View PubMed
  658. Nieminen AL, Gores GJ, Wray BE, Tanaka Y, Herman B, Lemasters JJ. Calcium dependence of bleb formation and cell death in hepatocytes. Cell Calcium. 1988 Dec; 9(5-6):237-46.
    View PubMed
  659. Herman B, Nieminen AL, Gores GJ, Lemasters JJ. Irreversible injury in anoxic hepatocytes precipitated by an abrupt increase in plasma membrane permeability. FASEB J. 1988 Feb; 2(2):146-51.
    View PubMed
  660. Gores GJ, Nieminen AL, Fleishman KE, Dawson Tl, Herman B, Lemasters JJ. Extracellular acidosis delays onset of cell death in ATP-deleted hepatocytes. Am J Physiol. 1988; 255(3 Part 1):C315-C322.
    View PubMed
  661. Herman B, Nieminem A-L, Gores GJ, and Lemasters JJ.. Bleb rupture and the onset of irreversible injury in isolated hepatocytes. Faseb J. 1988.
  662. Gores GJ, Moore SB, Fisher LD, Powell FC, Dickson ER. Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens. Hepatology. 1987 Sep-Oct; 7 (5):889-92
    View PubMed
  663. Gores GJ, Wiesner RH, Zinsmeister AR, Jorgensen RA, Dickson ER. Primary biliary cirrhosis and esophageal varices: development, natural history, and influence on survival. Gastroenterology. 1987 May; 92(PART 2):1736.
  664. Gores GJ, Kost LJ, LaRusso NF. The isolated perfused rat liver: conceptual and practical considerations. Hepatology. 1986 May-Jun; 6(3):511-7.
    View PubMed
  665. Gores GJ, LaRusso NF, Miller LJ. Hepatic processing of cholecystokinin peptides. I. Structural specificity and mechanism of hepatic extraction. Am J Physiol. 1986 Mar; 250(3 Pt 1):G344-9.
    View PubMed
  666. Gores GJ, Miller LJ, LaRusso NF. Hepatic processing of cholecystokinin peptides. II. Cellular metabolism, transport, and biliary excretion. Am J Physiol. 1986 Mar; 250(3 Pt 1):G350-6.
    View PubMed
  667. Gores GJ, Koeppe LE, Bartak DE. Electrochemical formation and decomposition of halogenated acetophenone anion radicals. J Org Chem. 1979; 44:380-385.
PST-20218869